[
  {
    "date": "2023-12-31",
    "symbol": "MOR",
    "period": "FY",
    "documenttype": "20-F",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "currentfiscalyearenddate": "--12-31",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-38455",
    "entityregistrantname": "MorphoSys AG",
    "entityincorporationstatecountrycode": "2M",
    "contactpersonnelname": "Lucinda Crabtree",
    "entityaddressaddressline1": "Semmelweisstrasse 7",
    "entityaddresspostalzipcode": 82152,
    "entityaddresscityortown": "Planegg",
    "entityaddresscountry": "DE",
    "cityareacode": 49,
    "localphonenumber": "89-89927-0",
    "security12btitle": "Ordinary Shares, no-par-value*",
    "tradingsymbol": "MOR",
    "securityexchangename": "NASDAQ",
    "entitycommonstocksharesoutstanding": 37655137,
    "documentperiodenddate": "2023-12-31",
    "entitywellknownseasonedissuer": "Yes",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Large Accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "true",
    "documentfinstmterrorcorrectionflag": "true",
    "documentfinstmtrestatementrecoveryanalysisflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityshellcompany": "false",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entitycentralindexkey": 1340243,
    "auditorlocation": "Munich, Germany",
    "auditorname": "PricewaterhouseCoopers GmbH",
    "auditorfirmid": 1275,
    "revenuefromsaleofgoods": 85036809,
    "revenuefromroyalties": 116385912,
    "licensesmilestonesandother": 36855592,
    "revenue": 238278313,
    "costofsales": 58354035,
    "grossprofit": 179924278,
    "researchanddevelopmentexpense": 283614139,
    "sellingexpense": 81369377,
    "generalandadministrativeexpense": 65797331,
    "impairmentlossrecognisedinprofitorlossgoodwill": 1619233,
    "operatingexpense": 432400080,
    "profitlossfromoperatingactivities": -252475802,
    "otherincome": 4967871,
    "otherexpensebynature": 7092650,
    "financeincome": 213362823,
    "financecosts": 141978551,
    "impairmentlossreversalofimpairmentlossrecognisedonfinancialassets": 468180,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -8174607,
    "incometaxexpensecontinuingoperations": -1188537,
    "profitloss": -189734199,
    "basicearningslosspershare": -5.53,
    "dilutedearningslosspershare": -5.53,
    "weightedaverageshares": 34312744,
    "adjustedweightedaverageshares": 34312744,
    "othercomprehensiveincomenetoftaxgainslossesfrominvestmentsinequityinstruments": 359458,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -27250608,
    "othercomprehensiveincome": -26891150,
    "comprehensiveincome": -216625349,
    "cashandcashequivalents": 158499651,
    "financialassetsatfairvaluethroughprofitorloss": 520845412,
    "tradereceivablesandcontractassets": 32093682,
    "currentfinancialassetsfromcollaboration": 3410247,
    "currentincometaxreceivables": 5284542,
    "othercurrentreceivables": 1496489,
    "inventories": 62068115,
    "currentprepaymentsandothercurrentassets": 30323373,
    "currentassets": 814021511,
    "propertyplantandequipment": 3890162,
    "rightofuseassets": 11100166,
    "intangibleassetsotherthangoodwill": 844109432,
    "goodwill": 342296501,
    "noncurrentfinancialassetsatamortisedcost": 1133982,
    "investmentsinassociatesaccountedforusingequitymethod": 2417968,
    "noncurrentprepaidexpensesandotherassets": 7341491,
    "noncurrentassets": 1212289702,
    "assets": 2026311213,
    "accountspayableandaccrualscurrent": 109804500,
    "currentleaseliabilities": 3628433,
    "currenttaxprovisions": 329723,
    "othershorttermprovisions": 4127121,
    "currentcontractliabilities": 19443663,
    "currentportionoflongtermborrowings": 1638125,
    "currentportionoffinancialliabilitiesfromcollaborations": 5526679,
    "currentportionoffinancialliabilitiesfromfuturepaymentstoroyaltypharma": 119811363,
    "currentliabilities": 264309607,
    "noncurrentleaseliabilities": 8796915,
    "otherlongtermprovisions": 28363134,
    "netdeferredtaxliabilities": 6549655,
    "longtermborrowings": 244020955,
    "financialliabilitiesfromcollaborationsnetofcurrentportion": 108868561,
    "financialliabilitiesfromfuturepaymentstoroyaltypharmalongterm": 1316353147,
    "noncurrentliabilities": 1712952367,
    "liabilities": 1977261974,
    "issuedcapital": 37655137,
    "treasuryshares": 1995880,
    "additionalpaidincapital": 938088474,
    "reserveofmiscellaneousothercomprehensiveincome": 88435451,
    "retainedearnings": -1013133943,
    "equity": 49049239,
    "equityandliabilities": 2026311213,
    "numberofsharesoutstanding": 53685,
    "issueofequityshares": 3423194,
    "issueofequity": 3423194,
    "increasedecreasethroughsharebasedpaymenttransactions": 5940339,
    "changesinequity": 7672,
    "saleorissueoftreasurysharesshares": -12295,
    "saleorissueoftreasuryshares": 454423,
    "increasedecreasethroughdisposalofinvestmentequity": 6271775,
    "othercomprehensiveincomenetoftaxavailableforsalefinancialassets": 359458,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 22276282,
    "adjustmentsfordepreciationandamortisationexpense": 10535352,
    "adjustmentinnetgainlossonsalesoffinancialassetsatfairvaluethroughprofitorloss": -24502933,
    "adjustmentinimpairmentlossreversalofimpairmentlossrecognisedonfinancialassets": 468180,
    "adjustmentsfordecreaseincreaseinderivativefinancialassets": 50028,
    "noncasheffectivenetchangesinfinancialassetsorfinancialliabilitiesfromcollaborations": 106731155,
    "noncasheffectivenetchangeinfinancialliabilitiesfromfuturepaymentstoroyaltypharma": 45666089,
    "gainonrepurchaseandinterestexpensefromconvertiblebond": -5340499,
    "adjustmentsforsharebasedpayments": 27370992,
    "cashincomefromsalesofsharesofinvestmentinassociates": 4238556,
    "shareofprofitlossofcontinuingoperationsofassociatesandjointventuresaccountedforusingequitymethod": -8174607,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": -4253268,
    "otheradjustmentstoreconcileprofitloss": 3798704,
    "adjustmentsforincometaxexpense": -1188537,
    "adjustmentsfordecreaseincreaseintradeaccountsreceivableandcontractassets": 56874720,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -24828127,
    "adjustmentsfordecreaseincreaseinaccountspayableandaccrualstaxprovisionsandotherprovisions": -44276990,
    "adjustmentsforincreasedecreaseindeferredincomeincludingcontractliabilities": 19443663,
    "incometaxespaidclassifiedasoperatingactivities": 1639294,
    "cashflowsfromusedinoperatingactivities": -295836943,
    "purchaseofavailableforsalefinancialassets": 3151166904,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 3142300000,
    "paymentsfromderivativefinancialinstruments": 50028,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 349467,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 2523224,
    "purchaseoffinancialassetsatfairvaluethroughothercomprehensiveincome": -4360421,
    "proceedsfromsalesofinterestsinassociates": 4578999,
    "interestreceivedclassifiedasinvestingactivities": 18224464,
    "cashflowsfromusedininvestingactivities": 15374261,
    "proceedsfromissuingshares": 102695820,
    "paymentsforshareissuecosts": 6650567,
    "repaymentsofbondsnotesanddebentures": 40256000,
    "paymentsfordebtissuecosts": 548856,
    "repaymentsofnoncurrentborrowings": 2382119,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 8023378,
    "interestpaidclassifiedasfinancingactivities": 1836396,
    "cashflowsfromusedinfinancingactivities": 42998504,
    "effectofexchangeratechangesoncashandcashequivalents": -6387075,
    "increasedecreaseincashandcashequivalents": -243851253,
    "disclosureofanalysisofincomestatementexplanatory": "Notes to the Statement of Profit or Loss",
    "notestothebalancesheettextblock": "Notes to the Balance Sheet",
    "disclosureofremunerationsystemformanagementboardandemployeesofgroupexplanatory": "Remuneration System for the Management Board and Employees of the Group",
    "descriptionofaccountingpolicyforbasisofandchangesinaccountingstandardspolicytextblock": "Basis of Application",
    "descriptionofconsolidationprinciplesexplanatorypolicytextblock": "Consolidation Principles",
    "disclosureofaccountingpoliciesforkeyestimatesandassumptionspolicytextblock": "Key Estimates and Assumptions",
    "descriptionofaccountingpoliciesappliedtolineitemsoftheincomestatementexplanatorypolicytextblock": "Accounting Policies applied to Line Items of the Statement of Profit or Loss",
    "descriptionofaccountingpolicyforrecognitionofcostofsalespolicytextblock": "Cost of Sales",
    "descriptionofaccountingpoliciesappliedtothelineitemsofthebalancesheetpolicytextblock": "Accounting Policies applied to Line Items of the Balance Sheet",
    "descriptionofaccountingpolicyforprepaidexpensesandotherassetspolicytextblock": "Prepaid Expenses and Other Assets",
    "descriptionofaccountingpolicyforcontractliabilitiespolicytextblock": "2.6.11    Contract LiabilitiesUpfront payments from customers for services to be rendered by the Group and revenue that must be recognized over a period of time are deferred and measured at the nominal amount of cash received. For current contract liabilities, the corresponding rendering of services and revenue recognition is expected to occur within a twelve-month period following the reporting date.",
    "disclosureofdetailedinformationaboutinsignificantinvestmentsinsubsidiariesexplanatorytabletextblock": "The following Group subsidiaries are included in the scope of consolidation, as shown in the table below.CompanyPurchase of Shares / EstablishmentIncluded in Basis of Consolidation sinceConstellation Pharmaceuticals, Inc., Boston, Massachusetts, USA July 202107/15/2021Constellation Securities Corp., Boston, Massachusetts, USA July 202107/15/2021MorphoSys US Inc., Boston, Massachusetts, USAJuly 201807/02/2018",
    "disclosureofestimatedusefullivesofpropertyplantandequipmentexplanatorytabletextblock": "Asset ClassUseful LifeDepreciation RatesOffice Equipment8 to 13 years13% - 8%Laboratory Equipment4 to 8 years25% - 13%Low-value Office and Laboratory EquipmentImmediately100 %Computer Hardware3 to 5 years33% - 20%Permanent Improvements to Property/Buildings10 years10 %",
    "disclosuredetailsofusefullivesofintangibleassetsincludinggoodwilltabletextblock": "Intangible Asset ClassUseful LifeAmortization RatesPatents10 years10 %Licenses and Licenses for Marketed Products8 - 24 years13% - 4%In-process R&D Programs and Internally Generated Intangible AssetsNot yet amortized, Impairment Only—Software3 years33%",
    "summaryofrevenuestabletextblock": "in 000' €202320222021Product Sales, Net85,037 84,899 66,861 Royalties116,386 99,871 65,576 License Fees151 56,389 43 Milestone Payments2,840 3,216 19,952 Service Fees15,028 19,365 19,726 Other18,836 14,527 7,454 Licenses, Milestones and Other36,855 93,497 47,175 Total238,278 278,267 179,612",
    "summaryofregionaldistributionofrevenuetabletextblock": "The following overview shows the Group’s regional distribution of revenue on the basis of the customer location:in 000' €202320222021Germany0 0 0 Europe (excluding Germany)26,794 28,739 19,075 Asia8 597 4,253 USA211,476 248,931 156,284 Total238,278 278,267 179,612",
    "satisfactionofperformanceobligationstabletextblock": "The following overview shows the timing of the satisfaction of performance obligations:in 000' €202320222021At a Point in Time223,251 258,831 159,843 Over Time15,028 19,437 19,769 Total238,278 278,267 179,612",
    "disclosureofdetailedinformationaboutcostofsalestabletextblock": "Cost of sales consisted of the following:in 000' €202320222021Expensed Acquisition or Production Cost of Inventories30,706 28,765 12,618 Personnel Expenses8,153 9,530 11,630 Impairment (+) and Reversals of Impairment (-) on Inventories7,400 0 0 Impairment, Amortization and Other Costs of Intangible Assets10,694 9,785 7,409 External Services1 31 289 Depreciation and Other Costs for Infrastructure1,300 404 221 Other Costs101 105 28 Total58,354 48,620 32,195",
    "disclosureofdetailedinformationaboutresearchanddevelopmentexpenseexplanatorytabletextblock": "Research and development expenses consisted of the following:in 000' €202320222021Personnel Expenses80,166 64,952 65,941 Consumable Supplies341 3,817 4,055 Impairment, Amortization and Other Costs of Intangible Assets16,337 14,799 7,859 External Services170,856 198,054 131,467 Depreciation and Other Costs for Infrastructure10,975 10,779 11,773 Other Costs4,939 5,411 4,116 Total283,614 297,812 225,211",
    "disclosureofsellingexpensetabletextblock": "Selling expenses consisted of the following:in 000' €202320222021Personnel Expenses39,820 48,562 63,517 Consumable Supplies4 49 86 Amortization of Intangible Assets136 162 138 External Services32,748 35,826 51,265 Depreciation and Other Costs for Infrastructure2,345 1,523 870 Other Costs6,316 6,280 5,667 Total81,369 92,402 121,543",
    "disclosureofdetailedinformationaboutgeneralandadministrativeexpenseexplanatorytabletextblock": "General and administrative expenses consisted of the following:in 000' €202320222021Personnel Expenses43,152 32,454 32,589 Consumable Supplies(327)115 88 Amortization of Intangible Assets1,064 1,213 596 External Services14,618 18,595 35,892 Depreciation and Other Costs for Infrastructure3,717 5,002 6,885 Other Costs3,573 2,765 2,242 Total65,797 60,144 78,292",
    "disclosureofdetailedinformationaboutpersonnelexpensesexplanatorytabletextblock": "Personnel expenses consisted of the following:in 000' €202320222021Wages and Salaries128,554 136,673 158,094 Social Security Contributions13,722 12,778 11,191 Share-based Payment Expense27,439 3,681 2,585 Other1,577 2,366 1,807 Total171,291 155,498 173,677",
    "averagenumberofemployeestabletextblock": "The following average number of employees were employed in the various functions in recent fiscal years.202320222021Production9 7 7 Research and Development365 438 440 Selling63 72 108 General and Administrative127 130 123 Total564 647 678",
    "disclosureofmajorcomponentsofincometaxtabletextblock": "in 000' €202320222021Current Tax Benefit / (Expense) (Thereof Regarding Prior Years: kEUR 1,464; 2022: kEUR (577); 2021: kEUR 96)1,464 (577)1,172 Deferred Tax Benefit / (Expenses)(275)(168,001)75,419 Total Income Tax Benefit / (Expenses)1,189 (168,578)76,591",
    "disclosureofdetailedinformationaboutinlimitedandunlimitedcarryforwardoftaxlossesexplanatorytabletextblock": "Due to the history of losses and the current uncertainties regarding the realization of planned taxable income, corresponding deferred tax assets on loss carry forwards were only recognized as outlined in the following table.",
    "disclosureofreconciliationofchangesindeferredtaxliabilityassetexplanatorytabletextblock": "Changes in Deferred Taxes in 2023in 000' €Income / (Expense)Direct Recognition in EquityFinancial Liabilities from Future Payments to Royalty Pharma7,633 0 Bonds4,074 0 Leases(478)0 Intangible Assets3,819 0 Receivables and Other Assets280 0 Property, Plant and Equipment116 0 Provisions(5)0 Other Liabilities(767)0 Tax Losses(14,716)0 Foreign Currency Translation Differences(231)0 Total(275)0",
    "summaryofcashandcashequivalentstabletextblock": "in 000' €12/31/202312/31/2022Bank Balances and Cash in Hand158,511 402,353 Impairment(11)(2)Cash and Cash Equivalents158,500 402,351",
    "summaryofinvestmentstabletextblock": "The financial assets at fair value, with changes recognized in profit or loss, are following.Unrealizedin 000' €MaturityCostGross ProfitLossesMarket ValueDecember 31, 2023Money Market Fundsdaily227,363 6,730 0 234,094 Total234,094 December 31, 2022Money Market Fundsdaily14,616 6 0 14,622 Total14,622",
    "summaryoffinancialassetsatamortizedcosttabletextblock": "The financial assets at amortized cost are shown in the following overview.in 000’ €MaturityCostEffective Interest Income (+) / Expense (-)ImpairmentCarrying AmountDecember 31, 2023Term Deposits, Current Portion1 to 12 months285,546 639 (201)285,984 Total285,984 December 31, 2022Term Deposits, Current Portion1 to 12 months490,000 881 (680)490,201 Total490,201",
    "summaryofaccountsreceivablebyregiontabletextblock": "The table below shows the accounts receivable by region as of the reporting date.in 000' €12/31/202312/31/2022Germany83 — Europe (excluding Germany)2,391 1,606 Asia16 — USA29,770 90,038 Impairment(166)(414)Total32,094 91,231",
    "summaryofantidilutionrightotherreceivabletabletextblock": "The anti-dilution right changed in 2023 and 2022 as follows.in 000' €20232022Balance as of January 19,832 0 Additions0 10,377 Gains/(losses) recognized in profit or loss statement(4,251)(386)Reclassification to investment in associates(5,581)(160)Balance as of December 310 9,832",
    "summaryofinventoriestabletextblock": "The table below shows inventories as of the reporting date. in 000' €12/31/202312/31/2022Raw materials, Supplies and Production Materials44,172 13,822 Finished Goods25,296 10,431 Impairment(7,400)0 Total62,068 24,253",
    "summaryofprepaidexpensesandotherassetstabletextblock": "The current prepaid expenses and other assets are shown in the following table.in 000' €12/31/202312/31/2022Receivables due from Tax Authorities from Input Tax Surplus3,780 5,669 Prepayments for External Laboratory Services1,711 5,937 Prepayments for Sublicenses3,193 2,082 Other Prepayments21,639 37,242 Total30,323 50,930",
    "summaryofnoncurrentprepaidexpensestabletextblock": "The non-current prepaid expenses and other assets are shown in the following table.in 000' €12/31/202312/31/2022Prepaid Expenses6,124 7,405 Other Assets1,217 1,324 Total7,341 8,729",
    "summaryofdepreciationtabletextblock": "Depreciation is contained in the following line items of profit or loss.in 000' €202320222021Research and Development1,557 1,818 1,681 Research and Development (Impairment)0 398 1,537 Selling226 113 63 General and Administrative532 958 1,089 Total2,315 3,287 4,370",
    "summaryofexpectedimpactofinitialapplicationofnewstandardsorinterpretationstabletextblock": "Lease agreements had the following effects on the statement of profit or loss.in 000' €202320222021Depreciation of Right-of-Use Assets4,607 3,942 3,648 Depreciation of Right-of-Use Assets (Change of Useful Life)3,673 0 0 Interest Expenses on Lease Liabilities924 1,051 1,157 Expenses for Short Term Leases0 256 1,553 Expenses for Leases of Low Value Assets31 19 17 Total9,235 5,268 6,375",
    "componentsofdepreciationrightofuseassetstabletextblock": "Depreciation of right-of-use assets is contained in the following line items of profit or loss.in 000' €202320222021Cost of Sales1,190 384 221 Research and Development4,533 1,897 1,636 Selling956 126 79 General and Administrative1,601 1,535 1,711 Total8,280 3,942 3,648",
    "disclosureofmaturityanalysisofleaseliabilitiestabletextblock": "The maturity analysis of the lease liabilities as of December 31, 2023, is as follows.December 31, 2023; in 000’ €Contractual Maturities of Financial LiabilitiesLess than 1 YearBetween One and Five YearsMore than 5 YearsTotal Contractual Cash FlowsCarrying Amount LiabilitiesLease Liabilities4,124 9,237 0 13,360 12,425",
    "summaryofamortizationofintangibleassetstabletextblock": "Amortization was included in the following line items of profit or loss.in 000' €202320222021Cost of Sales2,311 2,285 2,312 Cost of Sales (Impairment)0 0 0 Research and Development1,294 1,281 1,272 Research and Development (Impairment)9,584 7,875 13 Selling0 3 2 General and Administrative8 12 24 Total13,197 11,456 3,623",
    "summaryofaccountspayableandaccruedliabilitiestabletextblock": "Accounts payable and accruals are listed in the following table.in 000' €12/31/202312/31/2022Accounts Payable28,388 38,579 Accruals79,936 117,418 Other Liabilities1,481 1,273 Total109,805 157,270",
    "summaryofaccruedexpensestabletextblock": "Accruals are shown in the following overview:in 000' €12/31/202312/31/2022Accruals for External Laboratory Services37,002 78,737 Accrued Personnel Expenses for Payments to Employees and Management23,902 19,489 Accruals for Outstanding Invoices14,263 11,908 Accruals for Revenue Deductions from Product Sales1,878 2,364 Accruals for Legal Fees278 1,091 Accruals for Audit Fees and other related Costs378 1,790 Accruals for License Payments2,236 2,039 Total79,936 117,418",
    "summaryofauditfeestabletextblock": "The table below shows the total fees PwC Network received in the 2023 financial year.in 000' €12/31/202312/31/2022Audit Fees2,472 2,335 Fees for Other Assurance Services700 112 Other Fees for Other Services5 11 Total3,178 2,458",
    "summaryoftaxliabilitiescurrentandnoncurrenttabletextblock": "The table below shows the development of tax liabilities and current and non-current provisions in the 2023 financial year.in 000' €01/01/2023AdditionsUtilizationRelease12/31/2023Tax Liabilities793 0 (463)0 330 Provisions, current6,006 2,359 (2,196)(2,042)4,127 Provisions, non-current8,675 22,199 (686)(1,825)28,364 Total15,474 24,558 (3,345)(3,867)32,821",
    "summaryofcontractliabilitiestabletextblock": "The changes in this item are shown in the table below.",
    "summaryoffinancialassetsfromcollaborationstabletextblock": "The assets changed in 2023 as follows:",
    "summaryoffinancialliabilitiesfromfuturepaymentstoroyaltypharmatabletextblock": "in 000' €20232022Royalty Pharma - Financial Liability 1,058,317 1,141,884 thereof short-term111,028 102,171 thereof long-term947,289 1,039,713 Development Funding Bond 377,847 358,590 thereof short-term8,784 0 thereof long-term369,064 358,590 Balance as of Financial Liabilities from Future Payments to Royalty Pharma1,436,165 1,500,474 thereof short-term119,811 102,171 thereof long-term1,316,353 1,398,303",
    "summaryofroyaltypharmafinancialliabilitytabletextblock": "The \"Royalty Pharma - Financial Liability\" changed as follows in 2023 and 2022:in 000' €20232022Balance as of January 11,141,884 1,193,557 Addition0 0 Amortizations from Effective Interest Method56,623 66,672 Changes from Adjustments to Planning Assumptions(23,746)(28,285)Transfer of Assigned License Revenues to Royalty Pharma(110,957)(96,897)Foreign Currency Translation Differences from Consolidation(5,487)6,837 Balance as of December 311,058,317 1,141,884",
    "summaryofdevelopmentfundingbondtabletextblock": "The development funding bond changed as follows in 2023 and 2022:in 000' €20232022Balance as of January 1358,590 62,619 Cash Receipts0 295,421 Amortizations from Effective Interest Method32,414 11,746 Foreign Currency Translation Differences from Consolidation(13,157)(11,196)Balance as of December 31377,847 358,590",
    "summaryofinitialmeasurementdevelopmentfundingbondtabletextblock": "The development of the deferral of the initial measurement loss can be seen in the following table. The initial measurement loss is included as a deferral with a debit amount in the development funding bond.in 000' €20232022Balance as of January 152,862 0 Addition0 56,738 Amortization(4,640)(1,173)Foreign Currency Translation Differences from Consolidation(1,737)(2,703)December 3146,485 52,862",
    "scheduleoftreasurystocktabletextblock": "In the years 2023, 2022 and 2021, the Group did not repurchase any of its own shares. The composition and development of this line item are listed in the table below.Number of SharesValueBalance as of December 31, 2020131,414 4,868,744 Transfer in 2021(48,260)(1,783,690)Balance as of December 31, 202183,154 3,085,054 Transfer in 2022(17,174)(634,751)Balance as of December 31, 202265,980 2,450,303 Transfer in 2023(12,295)(454,423)Balance as of December 31, 202353,685 1,995,880",
    "summaryoffairvalueofstockoptionstabletextblock": "The parameters and fair value of each program are listed in the table below.",
    "summaryofdevelopmentoftheltiplanstabletextblock": "The table below shows the development of the LTI plans in the financial year 2023.April 2019 Long-Term Incentive ProgramOutstanding on January 1, 202318,821 Granted0 Adjustment due to Performance Criteria(6,526)Exercised(12,295)Forfeited0 Expired0 Outstanding on December 31, 20230 Exercisable on December 31, 20230 Weighted-average Exercise Price (€)n/a",
    "disclosureoffairvalueofperformancesharestabletextblock": "The parameters and the fair value of each program are listed in the table below.",
    "summaryoffairvalueofcashsettledprogramstabletextblock": "The parameters and the fair value of each program are listed in the table below.",
    "summaryofsharesofrelatedpartiestabletextblock": "Shares1/1/2023AdditionsSales12/31/2023Management BoardJean-Paul Kress, M.D.0 0 0 0 Sung Lee12,250 — — — Charlotte Lohmann21,168 157 0 1,325 Lucinda Crabtree, Ph.D.3— 0 0 0 Total3,418 157 0 1,325 Supervisory BoardMarc Cluzel, M.D., Ph.D.4,500 4,025 0 8,525 Michael Brosnan**5,000 0 0 5,000 Sharon Curran0 0 0 0 George Golumbeski, Ph.D.0 0 0 0 Andrew Cheng, M.D., Ph.D.0 00 0 Krisja Vermeylen2,000 1,000 0 3,000 Total11,500 5,025 0 16,525",
    "summaryofstockoptionsofrelatedpartiestabletextblock": "Stock Options1/1/2023AdditionsAdjustment due to Performance Criteria4ForfeituresExercises12/31/2023Management BoardJean-Paul Kress, M.D.81,989 0 (24,543)0 0 57,446 Sung Lee10 — — — — — Charlotte Lohmann24,595 0 (1,493)0 0 3,102 Lucinda Crabtree, Ph.D.3— 0 0 0 0 0 Total86,584 0 (26,036)0 0 60,548",
    "disclosuredetailsofremunerationtokeymanagerialpersonneltabletextblock": "The total compensation for key management personnel (Management Board and members of the Executive Committee) in 2023 and 2022 were as follows.in €20232022Total Short-Term Employee Benefits7,857,680 7,847,207 Total Post-Employment Benefits416,054 405,922 Total Termination Benefits0 320,248 Total Share-Based Payment10,060,828 1,317,464 Total Compensation18,334,562 9,890,841",
    "summaryofcarryingamountoffinancialinstrumentstabletextblock": "The totals of the carrying amounts of the financial instruments per measurement category are shown in the following overview.in 000' €Classification Financial Instrument12/31/202312/31/2022Financial Assets FVTPLFVTPL239,40624,454Financial Assets ACAC477,795985,107Financial Liabilities FLACFLAC(1,824,607)(2,053,071)",
    "summaryofnetgainsorlossesresultedfromfinancialinstrumentstabletextblock": "The following net gains or losses resulted from financial instruments in the financial year.in 000' €202320222021FVTPL9,553 7,051 10,983 AC19,095 9,064 9,824 FLAC39,065 231,387 (104,568)Total67,713 247,502 (83,761)",
    "summaryofgrossgainsorlossesresultedfromfinancialinstrumentstabletextblock": "The gross interest income and expenses from financial assets and liabilities measured at amortized cost are shown in the following table.in 000' €202320222021Interest Income AC18,316 4,618 723 Interest Expenses AC(21)(1,580)(2,415)Interest Income FLAC0 0 0 Interest Expenses FLAC(76,499)(102,144)(62,252)Total(58,204)(99,106)(63,944)",
    "summaryofgrosscarryingamountsoffinancialassetstabletextblock": "The gross carrying amounts of the Group's financial assets by credit risk rating class are as follows.",
    "summaryofsensitivityanalysisofforeignexchangeratestabletextblock": "in million €202320222021Increase of the Euro by 10%7.3 15.6 39.3 Decrease of the Euro by 10%(9.3)(19.7)(48.0)",
    "summaryofsensitivityanalysisofinterestraterisktabletextblock": "in million €202320222021Increase of the variable Interest Rate by 0.5%2.4 2.4 0.8 Decrease of the variable Interest Rate by 0.5%(2.4)(2.4)(0.8)The Group is currently not subject to significant interest rate risks from the account payables reported on the balance sheet.",
    "summaryofcapitalmanagementtabletextblock": "in 000' €12/31/202312/31/2022Stockholders’ Equity49,049 157,410 In % of Total Capital2.4 6.6 Total Liabilities1,977,262 2,239,523 In % of Total Capital97.6 93.4 Total Capital2,026,311 2,396,932",
    "summaryofdetailedinformationofliabilitiesarisingfromfinancialactivitiestabletextblock": "The following overview contains the presentation and development of the liabilities from financing activities. “Amortizations from Effective Interest Method,” “Changes from Adjustments to Planning Assumptions” and “Transfer of Assigned License Revenues to Royalty Pharma” include non-cash movements, including accrued interest expense.",
    "numberofsubsidiaries": 1,
    "maximumincreaseincreditriskpremiumbasispoints": 0.01,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P8Y",
    "depreciationratepropertyplantandequipment": 0.13,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P10Y",
    "amortisationrateintangibleassetsotherthangoodwill": 0.1,
    "numberofcashgeneratingunits": 1,
    "vestingrequirementsforsharebasedpaymentarrangementvestingperiod": "P4Y",
    "percentageofaccountsreceivable": 47,
    "revenuefromperformanceobligationssatisfiedorpartiallysatisfiedinpreviousperiods": 119200000,
    "employeebenefitsexpense": 128554000,
    "exercisepriceofoutstandingshareoptions2019": 34,
    "postemploymentbenefitexpensedefinedcontributionplans": 3200000,
    "numberofemployees": 9,
    "averagenumberofemployees": 524,
    "netforeignexchangegain": 3158000,
    "miscellaneousoperatingincome": 1810000,
    "netforeignexchangeloss": 6250000,
    "miscellaneousexpenses": 842000,
    "foreigncurrencygainsfromfinancialassetsfromcollaborations": 17526000,
    "gainsonchangeinfairvalueofderivatives": 7143000,
    "adjustmentsforfinanceincome": 149746000,
    "revenuefrominterest": 18316000,
    "gainfromrepurchaseofconvertiblebond": 16393000,
    "foreigncurrencylossesfromfinancialliabilitiesfromcollaborations": 8542000,
    "lossesonchangeinfairvalueofderivatives": 5306000,
    "interestexpenseforfinancialliabilitiesnotatfairvaluethroughprofitorloss": 104273000,
    "adjustmentsforfinancecosts": 18162000,
    "interestexpense": 4661000,
    "interestexpenseonleaseliabilities": 924000,
    "bankandsimilarcharges": 111000,
    "corporatetaxrate": 0.15,
    "solidaritysurchargerate": 0.055,
    "effectivetradetaxrate": 0.1085,
    "applicabletaxrate": 0.26675,
    "federalcorporateincometaxrate": 0.21,
    "averagestatetaxrate": 0.0638,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 300000,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": -1500000,
    "currenttaxexpenseincome": -1464000,
    "deferredtaxexpenseincome": 275000,
    "accountingprofit": 190923000,
    "taxexpenseincomeatapplicabletaxrate": -50929000,
    "taxeffectofsharebasedcompensation": 1463000,
    "taxeffectsofpermanentdifferences": 336000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 395000,
    "taxeffectofrevenuesexemptfromtaxation2011": 1213000,
    "taxeffectfromnonrecognitionofdeferredtaxassetsontemporarydifferences1": 15847000,
    "taxeffectfromnonrecognitionofdeferredtaxassetsoncurrentyeartaxlosses1": 32975000,
    "taxeffectofforeigntaxrates": 1312000,
    "taxeffectofprioryearadjustments": -1055000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": -320000,
    "averageeffectivetaxrate": 0.006,
    "prioryeartaxlossescarryforwards": 780297000,
    "currentyeartaxlossescarryforwards": 125486000,
    "foreigncurrencytranslation": -21238000,
    "reclassificationtotemporarydifference": 884545000,
    "expiryordeconsolidation": 207333000,
    "utilizationoftaxlosses": -78100000,
    "taxlossescarryforwards": 129233000,
    "taxlossesrelativetoustaxgroup": 150000000,
    "deferredtaxassetsontemporarydifferencesnotcapitalized": 15800000,
    "deferredtaxassets": 55495000,
    "deferredtaxliabilities": 397000,
    "numberofrestrictedstockunitsunvested": 630104,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 1996344,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -189734199,
    "cash": 158511000,
    "cashandcashequivalentsaccumulatedimpairments": 11000,
    "availableforsalefinancialassetscost": 227363000,
    "grossunrealizedgainsonfinancialassetsavailableforsale": 6730000,
    "currentfinancialassetsavailableforsale": 234094000,
    "financialassetfromescrow": 800000,
    "currentloansandreceivables": 285546000,
    "grossunrealizedgainsonloansandreceivables": 639000,
    "grossunrealizedlossesonloansandreceivables": 201000,
    "currenttradereceivables": 83000,
    "interestrevenueexpense": 18300000,
    "accountsreceivablenoninterestbearingpaymenttermsperiod": 20,
    "receivablesfromcontractswithcustomers": 14400000,
    "otherreceivables": 1000000,
    "impairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 4300000,
    "antidilutionrightotherreceivable": 5581000,
    "financialassets": 3800000,
    "additionstofinancialassets": 1854000,
    "gainslossesrecognisedinprofitorlossexcludingexchangedifferencesfairvaluemeasurementassets": -4251000,
    "reclassificationtoinvestmentsinassociatesfairvaluemeasurementassets": 5581000,
    "currentrawmaterialsandcurrentproductionsupplies": 44172000,
    "finishedgoods": 25296000,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorlossinventories": 7400000,
    "contractliabilitiesprepaymentsreceived": 19400000,
    "receivablesfrominputtaxsurplus": 3780000,
    "currentprepaidexpenses": 1711000,
    "othercurrentprepayments": 21639000,
    "noncurrentprepaidexpenses": 6124000,
    "othernoncurrentassets": 1217000,
    "noncurrentrestrictedcashandcashequivalents": 1000000,
    "restrictedcashascollateralforcreditcards": 200000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 389000,
    "disposalspropertyplantandequipment": 38000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -33000,
    "depreciationpropertyplantandequipment": 1671000,
    "depreciationexpense": 1557000,
    "leaseliabilities": 12425000,
    "additionstorightofuseassets": 2000,
    "additionforleaseliabilities": 1505000,
    "depreciationrightofuseassets": 6966000,
    "leasepayments": 8581000,
    "disposalofrightofuseassets": -27000,
    "rightofuseassetsincreasedecreaseinrevaluationsurplus": -25855000,
    "leaseliabilitieschangeinvalueincreasedecrease": -27054000,
    "foreignexchangegainlossrightofuseassets": -102000,
    "foreignexchangegainlossleaseliabilities": -150000,
    "depreciationrightofuseassetsaftercurrencytranslation": 4607000,
    "depreciationadjustmentofrightofuseassetsduetochangeofusefullife": 3673000,
    "otherinterestexpenseleaseliability": 924000,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 31000,
    "impactonprofitorlossduetoadoptionoflease": 9235000,
    "netleaseliabilities": 4124000,
    "futureleasepaymentsdiscounted": 25300000,
    "intangibleassetsandgoodwill": 13866000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 102000,
    "disposalsintangibleassetsotherthangoodwill": 3000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": -27679000,
    "amortizationchargefortheyear": 234000,
    "impairmentlossofintangibleassetsandgoodwill": 8877000,
    "valueinusepatenttermusedforcalculation": "P21Y",
    "betafactor": 1.6,
    "weightedaveragecostofcapitalbeforetaxpercentage": 0.159,
    "fairvalue": 768800000,
    "capitalizedrdprogram": 766700000,
    "reductionincashflowforecast": 0.49,
    "discountrate": 0.094,
    "actuarialassumptionofdiscountrates": 0.054,
    "levelofparticipationofentitycomparedwithotherparticipatingentities": 0.121,
    "milestoneshares": 67500000,
    "milestonepayments": 500000000,
    "expectedlicensingpayments": 500000000,
    "otherassets": 1544000,
    "financialliabilities": 712000,
    "otherfinancialliabilities": 11383000,
    "equityinassociate": 4694000,
    "depreciationandamortisationexpense": 185000,
    "decreasethroughsaleofsharesofinvestmentinassociates": 340000,
    "tradeaccountspayable": 28388000,
    "accruedliabilities": 79936000,
    "othercurrentliabilities": 1481000,
    "accountspayableandaccruedexpensescurrent": 109805000,
    "externallaboratoryservices": 37002000,
    "accruedpersonnelexpensesforpaymentstoemployeesandmanagement": 23902000,
    "accruedoutstandingexpense": 14263000,
    "accruedrevenuedeductionsfromproductsales": 1878000,
    "expensesforlegaladvice": 278000,
    "auditfeesandotherauditrelatedcosts": 378000,
    "licensepayments": 2236000,
    "accruedliabilitycurrent": 79936000,
    "auditfees": 2472000,
    "otherauditrelatedcosts": 700000,
    "otherfeesandotherservices": 5000,
    "taxliabilitiescurrentandnoncurrent": 300000,
    "provisions": 32500000,
    "otherprovisions": 32821000,
    "additionalprovisionsotherprovisions": 2359000,
    "provisionusedotherprovisions": 463000,
    "unusedprovisionreversedotherprovisions": 2042000,
    "contractliabilities": 19444000,
    "notionalamount": 100000,
    "numberofbondsissued": 2621,
    "nominalamountbondissuedpercentage": 1,
    "debtcouponrate": 0.00625,
    "debtconversionprice": 131.29,
    "intialconversionofcovertiblebondstoordinaryshares": 2475436,
    "redemptionpercentageofdebtinstrumentwhenmarketpriceofsharesfalldown": 1.3,
    "redemptionpercentagebasedonoutstandingnominalamount": 0.2,
    "convertiblebondsportionofvotinginterestacquirable": 0.3,
    "issueofconvertibleinstruments": 49200000,
    "liabilitycomponentofconvertiblebond": 270700000,
    "revenuerecognitionmilestonemethodrevenuerecognized": 1100000000,
    "percentageonshareofprofitlossofassociatesandjointventures": 0.5,
    "currentfinancialliabilities": 6100000,
    "noncurrentfinancialliabilities": 120300000,
    "foreignexchangeloss": 7700000,
    "incomefromnetcasheffects": -2400000,
    "percentageofsharesindevelopmentcost": 0.55,
    "percentageoffuturedevelopmentcostsforclinicaltrials": 1,
    "financialassetsatfairvalue": 3410000,
    "increaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": 4000000,
    "decreaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": -4000000,
    "financialliabilitiesfromfuturepaymentstoroyaltypharmalongandshortterm": 1058317000,
    "amortizationfromeffectiveinterestmethod": 56623000,
    "transferofassignedlicenserevenuestoroyaltypharma": -110957000,
    "gainslossesonexchangedifferencesontranslationnetoftax": -5487000,
    "percentageofroyaltiesfromnetsales": 1,
    "percentageoffuturenetsales": 0.03,
    "borrowingsinterestrate": 0.133,
    "marketinequity": 57600000,
    "developmentfundingbondmeasurementloss": 46485000,
    "numberofsharesissued": 37655137,
    "numberoftreasuryshares": 53685,
    "numberofvotingrightsatannualgeneralmeeting": 1,
    "numberofsharesauthorised": 8909562,
    "authorisedcapitalamount": 8909562,
    "maximumauthorisedtermforsharecapitalincrease": "P5Y",
    "numberofsharesofconditionalcapital": 6688406,
    "capitalreserve": 6688406,
    "sharecapitalpercentage": 0.1,
    "increasedecreaseinnumberthroughtransferoftreasuryshares": -12295,
    "increasedecreaseintreasurystockamountduetotransfer": 454423,
    "numberofperformanceshares": 12295,
    "increaseincapitalreserve": 104379750,
    "reserveofchangeinvalueoftimevalueofoptions": 331972,
    "reserveofexchangedifferencesontranslation": 88103480,
    "subscriptionright": 0.29,
    "weightedaverageshareprice2019": 55.52,
    "maximumtermforexerciseofoptionsgrantedforsharebasedpaymentarrangement": "P3Y",
    "performancerequirementsforsharebasedpaymentarrangementperformanceandvestingperiod": "P4Y",
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 72650,
    "numberofinstrumentsgrantedinsharebasedpaymentarrangement": 79935,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 12295,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 51358,
    "numberofoutstandingshareoptions": 32535,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 384,
    "numberofgrantedsubscriptionrights": 2,
    "accumulatedperiodofabsencesharebasepaymentcriteria": "P90D",
    "portionofshareoptionsforfeitedincaseofabsence": 0.02083,
    "periodofabsencesharebasepaymentcriteria": "P30D",
    "performancecriteriapercentageshareunitplan": 0.25,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 494979,
    "sharebasedcompensationbysharebasedpaymentarrangementadjustmentduetoperformancecriteria": -48706,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": -469,
    "numberofinstrumentsexercisableonreportingdate": 68305,
    "expectedvolatilitydevelopmentterm": "P4Y",
    "weightedaveragesharepriceshareoptionsgranted2019": 85,
    "strikepriceshareoptionsgranted": 87.86,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.3776,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.02,
    "weightedaveragefairvalueatmeasurementdateshareoptionsgranted": 31.81,
    "companyfactor": 1,
    "numberofsharesissuedtorelatedpartiesduringperiodadditions": 157,
    "sharebasedpaymentarrangementindividualperformanceperiod": "P1Y",
    "numberofperformanceperiods": 3,
    "percentageofsharesdesignated": 0.4,
    "percentageofbeneficiariesleavingcompany": 0.25,
    "targetachievement": 1,
    "liabilitiesfromsharebasedpaymenttransactions2011": 290378,
    "expensefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 28242,
    "transferofperformancesharestobeneficiariesperiod": "P3M",
    "paymentstoandonbehalfofemployees": 178790,
    "remainingperformanceperiodforsharebasedpaymentarrangement": "P0Y3M",
    "riskfreeinterestrate": 0.0356,
    "receivablesduefromassociates": 500000,
    "percentageoffixedannualgrosssalaryforretirementplanbenefit": 0.1,
    "percentageoffixedannualgrosssalaryforprovidentfund": 0.1,
    "sharebasedpaymentsvestingrightsminimumshareholding": 0.3,
    "weightedtargetperformanceachievement": 1.5971,
    "keymanagementpersonnelcompensation": 8279615,
    "performanceunrelatedcompensation": 1955735,
    "performancerelatedcompensation": 1898880,
    "keymanagementpersonnelcompensationsharebasedpayment": 4425000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 416054,
    "compensationofformeremployees": 900000,
    "adjustmentsfordecreaseincreaseinaccruedincomeotherthancontractassets": 3700000,
    "numberofrestrictedsharesexercisableinsharebasedpaymentarrangement": 47916,
    "numberofsharesissuedtorelatedparties": 5000,
    "numberofamericandepositorysharesheld": 20000,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": -157,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 7857680,
    "keymanagementpersonnelcompensationterminationbenefits": 7000000,
    "remunerationofsupervisoryboard": 104210,
    "sharedbasedpaymentprograms": 1113000,
    "othercommitment": 1883000,
    "contractualobligation": 2996000,
    "futurepaymentcommitmentsforclinicalstudies": 133700000,
    "milestonepayment": 236500000,
    "deferredincomefromobligationstoroyaltypharma": 786400000,
    "contingentliabilitiesincurredinrelationtointerestsinassociates": 226800000,
    "otherfinancialassets": 520845000,
    "currentinvestments": 234094000,
    "investmentsfixedtermdeposits": 285984000,
    "otherreceivablesfinancialassets": 1496000,
    "otherreceivablesthereofnonfinancialassets": 1496000,
    "othercurrentnonfinancialassets": 30323000,
    "currentfinancialassets": 714849000,
    "noncurrentinvestments": 1134000,
    "thereoffinancialassetsfromescrownoncurrent": 1134000,
    "longtermrestrictedcash": 1217000,
    "othernoncurrentnonfinancialassets": 6124000,
    "noncurrentfinancialassets": 2351000,
    "tradeandothercurrentpayables": 28388000,
    "othernonfinancialliabilities": 81417000,
    "currentconvertiblebond": 1638000,
    "currentfinancialliabilitiesfromcollaboration": 5527000,
    "noncurrentconvertiblebond": 244021000,
    "noncurrentfinancialliabilitiesfromcollaboration": 108869000,
    "currentfinancialassetsatfairvaluethroughprofitorloss": 239406000,
    "currentfinancialassetsatamortisedcost": 477795000,
    "currentfinancialliabilitiesatamortisedcost": 1824607000,
    "gainslossesrecognisedinothercomprehensiveincomeexcludingexchangedifferencesfairvaluemeasurementassets": 6272000,
    "salesfairvaluemeasurementassets": 6272000,
    "cumulativegainlossondisposalofinvestmentsinequityinstrumentsdesignatedasmeasuredatfairvaluethroughothercomprehensiveincome": 6300000,
    "fairvalueofinvestmentsinequityinstrumentsmeasuredatfairvaluethroughothercomprehensiveincomeatdateofderecognition": 6700000,
    "gainlossonfinancialinstruments": 9553000,
    "interestincomeforfinancialassetsmeasuredatamortisedcost": 18316000,
    "interestexpensesonfinancialassetsatamortisedcost": 21000,
    "interestexpenseonotherfinancialliabilities": 76499000,
    "grossgainslossesonfinancialinstruments": -58204000,
    "maximumexposuretocreditriskondebtinstruments": 238300000,
    "maximumexposuretocreditriskonfinancialguarantees": 1200000,
    "impairmentlossonfinancialasset": -229000,
    "unusedprovisionamountsreversed": 697000,
    "increasedecreaseinimpairmentlossforcreditriskrecognizedinprofitorloss": -229000,
    "grosscarryingamountoffinancialassets": 158511000,
    "convertiblebondsduetorelatedparties": 1638000,
    "financialliabilitiesfromcollaboration": 5665000,
    "financialassetsfromcollaboration": 3410000,
    "foreigncurrencyriskexposurenet": -105852000,
    "foreignexchangesensitivityanalysis": 7300000,
    "equitycapitalpercentage": 0.024,
    "liabilitiescapitalpercentage": 0.976,
    "liabilitiesarisingfromfinancingactivities": 12425000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 8581000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": -1505000,
    "increasedecreasethroughgainonrepurchaseofconvertiblebond": 16393000,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": 104669000,
    "increasedecreasethroughchangesinfairvaluesliabilitiesarisingfromfinancingactivities": 27054000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": 150000,
    "noncurrentassetsexcludingdeferredtaxassets": 90600000,
    "additionspropertyplantandequipmentandintangibleassets": 2900000,
    "expirationtermforlastvalidclaimtafasitamablicensedpatent": "P11Y",
    "paymentsfromhibio": 500000000,
    "upfrontpayment": 15000000,
    "borrowings": 245700000,
    "reductioninworkforceduetobusinesscombinationpercentage": 0.07,
    "restructuringprovision": 5000000
  },
  {
    "date": "2022-12-31",
    "symbol": "MOR",
    "period": "FY",
    "documenttype": "20-F",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "currentfiscalyearenddate": "--12-31",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentperiodenddate": "2022-12-31",
    "entityfilenumber": "001-38455",
    "entityregistrantname": "MorphoSys AG",
    "entityincorporationstatecountrycode": "2M",
    "contactpersonnelname": "Sung Lee",
    "entityaddressaddressline1": "Semmelweisstrasse 7",
    "entityaddresspostalzipcode": 82152,
    "entityaddresscityortown": "Planegg",
    "entityaddresscountry": "DE",
    "cityareacode": 49,
    "localphonenumber": "89-89927-0",
    "security12btitle": "Ordinary Shares, no-par-value*",
    "tradingsymbol": "MOR",
    "securityexchangename": "NASDAQ",
    "entitycommonstocksharesoutstanding": 34231943,
    "entitywellknownseasonedissuer": "Yes",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Large Accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "true",
    "entityshellcompany": "false",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entitycentralindexkey": 1340243,
    "auditorname": "PricewaterhouseCoopers GmbH",
    "auditorfirmid": 1275,
    "auditorlocation": "Munich, Germany",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "revenuefromsaleofgoods": 84899483,
    "revenuefromroyalties": 99870756,
    "licensesmilestonesandother": 93496764,
    "revenue": 278267003,
    "costofsales": 48619885,
    "grossprofit": 229647118,
    "researchanddevelopmentexpense": 297812160,
    "sellingexpense": 92402354,
    "generalandadministrativeexpense": 60143637,
    "operatingexpense": 450358151,
    "profitlossfromoperatingactivities": -220711033,
    "otherincome": 11964616,
    "otherexpensebynature": 15584261,
    "financeincome": 412065798,
    "financecosts": 165897761,
    "impairmentlossreversalofimpairmentlossrecognisedonfinancialassets": -12000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -4305026,
    "incometaxexpensecontinuingoperations": 168578523,
    "profitloss": -151058190,
    "earningspersharebasicanddiluted": -4.42,
    "basicearningslosspershare": -4.42,
    "dilutedearningslosspershare": -4.42,
    "weightedaveragenumberofequitysharesusedincomputingearningspersharebasicanddiluted": 34155650,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 62569010,
    "othercomprehensiveincome": 62569010,
    "comprehensiveincome": -88489180,
    "cashandcashequivalents": 402350904,
    "financialassetsatfairvaluethroughprofitorloss": 504822678,
    "tradereceivablesandcontractassets": 91231143,
    "currentincometaxreceivables": 2601052,
    "othercurrentreceivables": 12852390,
    "inventories": 24252987,
    "currentprepaymentsandothercurrentassets": 50929633,
    "currentassets": 1089040787,
    "propertyplantandequipment": 5926942,
    "rightofuseassets": 45060360,
    "intangibleassetsotherthangoodwill": 886582956,
    "goodwill": 356239773,
    "investmentsinassociatesaccountedforusingequitymethod": 5352451,
    "deferredtaxassets": 47465000,
    "noncurrentprepaidexpensesandotherassets": 8728994,
    "noncurrentassets": 1307891476,
    "assets": 2396932263,
    "accountspayableandaccrualscurrent": 157270380,
    "currentleaseliabilities": 7561126,
    "currenttaxprovisions": 792675,
    "otherprovisions": 6006229,
    "currentportionoflongtermborrowings": 2031250,
    "currentportionoffinancialliabilitiesfromcollaborations": 2513718,
    "currentportionoffinancialliabilitiesfromfuturepaymentstoroyaltypharma": 102171167,
    "currentliabilities": 278346545,
    "noncurrentleaseliabilities": 38219225,
    "otherlongtermprovisions": 8674110,
    "netdeferredtaxliabilities": 6506420,
    "longtermborrowings": 291647407,
    "financialliabilitiesfromcollaborationsnetofcurrentportion": 217825779,
    "financialliabilitiesfromfuturepaymentstoroyaltypharmalongterm": 1398303228,
    "noncurrentliabilities": 1961176169,
    "liabilities": 2239522714,
    "issuedcapital": 34231943,
    "treasuryshares": 2450303,
    "additionalpaidincapital": 833708724,
    "reserveofmiscellaneousothercomprehensiveincome": 115326601,
    "retainedearnings": -823407416,
    "equity": 157409549,
    "equityandliabilities": 2396932263,
    "equitybeginningbalanceshares": 34231943,
    "increasedecreasethroughsharebasedpaymenttransactions": 1022786,
    "saleorissueoftreasuryshares": 634751,
    "saleorissueoftreasurysharesshares": -17174,
    "equityendingbalanceshares": 34231943,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 7805764,
    "adjustmentsfordepreciationandamortisationexpense": 10535414,
    "adjustmentinnetgainlossonsalesoffinancialassetsatfairvaluethroughprofitorloss": -3205253,
    "adjustmentinimpairmentlossreversalofimpairmentlossrecognisedonfinancialassets": -12000,
    "adjustmentsfordecreaseincreaseinderivativefinancialassets": -212445,
    "noncasheffectivenetchangesinfinancialassetsorfinancialliabilitiesfromcollaborations": 301066774,
    "noncasheffectivenetchangeinfinancialliabilitiesfromfuturepaymentstoroyaltypharma": 46764425,
    "noncasheffectivechangeoffinanicalliabilitiesaytamortizedcost": 12502457,
    "adjustmentsforsharebasedpayments": 3638977,
    "noncashincomefromcapitalizationofinvestmentinassociates": -19874779,
    "shareofprofitlossofcontinuingoperationsofassociatesandjointventuresaccountedforusingequitymethod": 4305026,
    "adjustmentsforincometaxexpense": 168578523,
    "adjustmentsfordecreaseincreaseintradeaccountsreceivableandcontractassets": -18165270,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -11924577,
    "adjustmentsfordecreaseincreaseinaccountspayableandaccrualstaxprovisionsandotherprovisions": -21092954,
    "adjustmentsforincreasedecreaseindeferredincomeincludingcontractliabilities": -252594,
    "incometaxespaidclassifiedasoperatingactivities": 466161,
    "cashflowsfromusedinoperatingactivities": -366705261,
    "purchaseofavailableforsalefinancialassets": 1884857008,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 2240651170,
    "proceedsfromderivativefinancialinstruments": 212445,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 1932486,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 13296176,
    "interestreceivedclassifiedasinvestingactivities": 4225330,
    "cashflowsfromusedininvestingactivities": 345003275,
    "proceedsfromnoncurrentborrowings": 23774611,
    "cashreceiptsfromcontractsforfuturepaymentstoroyaltypharma": -295420975,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 3412760,
    "interestpaidclassifiedasfinancingactivities": 4365151,
    "cashflowsfromusedinfinancingactivities": 311417675,
    "effectofexchangeratechangesoncashandcashequivalents": -10613041,
    "increasedecreaseincashandcashequivalents": 279102648,
    "mandatoryapplicationforfinancialyearsstartingdate": "01/01/2022",
    "adoptedbytheeuropeanunionstatus": "yes",
    "impactonmorphosysstatus": "none",
    "possibleimpactonmorphosysstatus": "none",
    "basisofconsolidationbeginningdate": "07/15/2021",
    "descriptionofusefullifepropertyplantandequipment": "8 to 13 years",
    "descriptionofusefullifeintangibleassetsotherthangoodwill": "10 years",
    "revenuefromperformanceobligationssatisfiedorpartiallysatisfiedinpreviousperiods": 103100000,
    "employeebenefitsexpense": 136673000,
    "postemploymentbenefitexpensedefinedcontributionplans": 4300000,
    "numberofemployees": 7,
    "averagenumberofemployees": 629,
    "netforeignexchangegain": 11426000,
    "miscellaneousoperatingincome": 539000,
    "netforeignexchangeloss": 15030000,
    "miscellaneousexpenses": 554000,
    "foreigncurrencygainsfromfinancialassetsfromcollaborations": 14260000,
    "gainsonchangeinfairvalueofderivatives": 7596000,
    "adjustmentsforfinanceincome": 385592000,
    "revenuefrominterest": 4618000,
    "foreigncurrencylossesfromfinancialliabilitiesfromcollaborations": 45645000,
    "lossesonchangeinfairvalueofderivatives": 545000,
    "interestexpenseforfinancialliabilitiesnotatfairvaluethroughprofitorloss": 112717000,
    "adjustmentsforfinancecosts": 2917000,
    "interestexpense": 2752000,
    "interestexpenseonleaseliabilities": 1051000,
    "bankandsimilarcharges": 271000,
    "currenttaxexpenseincome": 577000,
    "deferredtaxexpenseincome": 168001000,
    "adjustmentsforcurrenttaxofpriorperiod": -577000,
    "corporatetaxrate": 0.15,
    "solidaritysurchargerate": 0.055,
    "effectivetradetaxrate": 0.1085,
    "applicabletaxrate": 0.26675,
    "federalcorporateincometaxrate": 0.21,
    "averagestatetaxrate": 0.0653,
    "deferredtaxexpensefromreversalandnonrecognitionofimpairmentandtemporarydifferences": -132800000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": 20500000,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": -600000,
    "accountingprofit": -17520000,
    "taxexpenseincomeatapplicabletaxrate": 4674000,
    "taxeffectofsharebasedcompensation": 358000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 574000,
    "taxeffectfromnonrecognitionofdeferredtaxassetsontemporarydifferences1": 112354000,
    "taxeffectfromnonrecognitionofdeferredtaxassetsoncurrentyeartaxlosses1": 45953000,
    "taxeffectofforeigntaxrates": 4617000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 49000,
    "averageeffectivetaxrate": 9.622,
    "prioryeartaxlossescarryforwards": 724749000,
    "currentyeartaxlossescarryforwards": 20129000,
    "foreigncurrencytranslation": 35419000,
    "reclassificationtotemporarydifference": 780297000,
    "expiryordeconsolidation": 189902000,
    "utilizationoftaxlosses": -45953000,
    "taxlossescarryforwards": 143949000,
    "deferredtaxliabilities": 8897000,
    "taxlossesrelativetoustaxgroup": 216600000,
    "deferredtaxassetsontemporarydifferencesnotcapitalized": 112400000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -168000000,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -151058190,
    "weightedaverageshares": 34155650,
    "adjustedweightedaverageshares": 34155650,
    "numberofrestrictedstockunitsunvested": 326669,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 2475437,
    "cash": 402353000,
    "cashandcashequivalentsaccumulatedimpairments": 2000,
    "availableforsalefinancialassetsmaturity": "daily",
    "availableforsalefinancialassetscost": 14616000,
    "grossunrealizedgainsonfinancialassetsavailableforsale": 6000,
    "currentfinancialassetsavailableforsale": 14622000,
    "netgainfromdisposalofavailableforsalefinancialassets": 200000,
    "currentloansandreceivables": 490000000,
    "grossunrealizedgainsonloansandreceivables": 881000,
    "grossunrealizedlossesonloansandreceivables": 680000,
    "loansandreceivablesmaturity": "4 to 12 months",
    "netgainfromdisposaloffinancialassetsatfairvaluethroughprofitandloss": 3000000,
    "currenttradereceivables": 1606000,
    "accountsreceivablenoninterestbearingpaymentterms": "between 30 and 180 days",
    "receivablesfromcontractswithcustomers": 51400000,
    "percentageofaccountsreceivable": 0.56,
    "otherreceivables": 2000000,
    "antidilutionrightotherreceivable": 9800000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 10377000,
    "currentrawmaterialsandcurrentproductionsupplies": 13822000,
    "finishedgoods": 10431000,
    "receivablesfrominputtaxsurplus": 5669000,
    "currentprepaidexpenses": 5937000,
    "othercurrentprepayments": 37242000,
    "prepaidexpensesandothercurrentassets": 50930000,
    "noncurrentprepaidexpenses": 7405000,
    "othernoncurrentassets": 1324000,
    "noncurrentrestrictedcashandcashequivalents": 1100000,
    "restrictedcashascollateralforcreditcards": 200000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 1769000,
    "disposalspropertyplantandequipment": 2244000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 147000,
    "depreciationpropertyplantandequipment": 2205000,
    "impairmentlossrecognisedinprofitorlosspropertyplantandequipment": 349000,
    "depreciationexpense": 1818000,
    "leaseliabilities": 45781000,
    "additionstorightofuseassets": 2146000,
    "additionforleaseliabilities": 6224000,
    "depreciationrightofuseassets": 3424000,
    "leasepayments": 4446000,
    "foreignexchangegainlossrightofuseassets": 280000,
    "foreignexchangegainlossleaseliabilities": 368000,
    "depreciationrightofuseassetsaftercurrencytranslation": 3942000,
    "otherinterestexpenseleaseliability": 1051000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 256000,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 19000,
    "impactonprofitorlossduetoadoptionoflease": 5268000,
    "netleaseliabilities": 6554,
    "intangibleassetsandgoodwill": 13767000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 68000,
    "disposalsintangibleassetsotherthangoodwill": 4551000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 46414000,
    "amortizationchargefortheyear": 197000,
    "impairmentlossofintangibleassetsandgoodwill": 42000,
    "milestonepaymentswerecapitalized": 10400000,
    "betafactor": 1,
    "weightedaveragecostofcapitalbeforetaxpercentage": 0.114,
    "capitalizedrdprogram": 794300000,
    "fairvalue": 796500000,
    "descriptionofgrowthrateusedtoextrapolatecashflowprojections": 0.01,
    "discountrate": 0.013,
    "otherassets": 833000,
    "financialliabilities": 10334000,
    "otherfinancialliabilities": 609000,
    "equityinassociate": 3176000,
    "depreciationandamortisationexpense": 58000,
    "milestonepayments": 500000000,
    "milestoneshares": 67500000,
    "licensingpayments": 15000000,
    "expectedlicensingpayments": 500000000,
    "increasedecreaseindeferredtaxliabilityasset": -168000000,
    "tradeaccountspayable": 38579000,
    "accruedliabilities": 117418000,
    "othercurrentliabilities": 1273000,
    "accountspayableandaccruedexpensescurrent": 157270000,
    "externallaboratoryservices": 78737000,
    "accruedpersonnelexpensesforpaymentstoemployeesandmanagement": 19489000,
    "accruedoutstandingexpense": 11908000,
    "accruedrevenuedeductionsfromproductsales": 2364000,
    "expensesforlegaladvice": 1091000,
    "auditfeesandotherauditrelatedcosts": 1790000,
    "licensepayments": 2039000,
    "accruedliabiitycurrent": 117418000,
    "auditfees": -2335000,
    "otherauditrelatedcosts": -112000,
    "otherfeesandotherservices": -11000,
    "taxliabilitiescurrentandnoncurrent": 800000,
    "currentprovisions": 6006000,
    "noncurrentprovisions": 8227000,
    "taxprovisionsandcurrentandnoncurrentotherprovisions": 14531000,
    "provisions": 14700000,
    "contractliabilitiesprepaymentsreceived": 37109000,
    "revenuethatwasincludedincontractliabilitybalanceatbeginningofperiod": 253000,
    "revenuerecognizedforreceivedprepaymentsandservicesperformed": -37109000,
    "nominalamountbond": 1,
    "issueofconvertibleinstruments": 49200000,
    "liabilitycomponentofconvertiblebond": 270700000,
    "notionalamount": 325000000,
    "numberofsharesissued": 3250,
    "debtcouponrate": 0.00625,
    "debtconversionprice": 131.29,
    "debtinstrumentconvertiblenumberofequityinstruments": 2475436,
    "redemptionpercentageofdebtinstrumentwhenmarketpriceofsharesfalldown": 1.3,
    "redemptionpercentagebasedonoutstandingnominalamount": 0.2,
    "proportionofvotingpowerheldinsubsidiary": 0.3,
    "interestexpenseondebtinstrumentsissued": 325000000,
    "decreasethroughderecognitionfinancialassets": 23768000,
    "revenuerecognitionmilestonemethodrevenuerecognized": 1100000000,
    "percentageonshareofprofitlossofassociatesandjointventures": 0.5,
    "financialassets": 1009561000,
    "percentageofsharesindevelopmentcost": 0.55,
    "percentageoffuturedevelopmentcostsforclinicaltrials": 1,
    "currentfinancialliabilities": 2700000,
    "noncurrentfinancialliabilities": 232300000,
    "foreignexchangeloss": 37400000,
    "increaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": 5500000,
    "decreaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": -5500000,
    "financialliabilitiesfromfuturepaymentstoroyaltypharmalongandshortterm": 1141884000,
    "amortizationfromeffectiveinterestmethod": 66672000,
    "increaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsrecognisedinprofitorlossaftertaxliabilities": 28285000,
    "transferofassignedlicenserevenuestoroyaltypharma": -96897000,
    "gainslossesonexchangedifferencesontranslationnetoftax": 6837000,
    "cashreceiptsfromdevelopmentfundingbond": 300000000,
    "cashpaymentsdevelopmentfundingbond": 150000000,
    "marketinequity": 57600000,
    "developmentfundingbondmeasurementloss": 52862000,
    "weightedaverageshareprice2019": 55.52,
    "numberofsharesauthorised": 9195696,
    "numberofsharesofconditionalcapital": 6804134,
    "notionalamountpercent": -0.1,
    "numberoftreasuryshares": 65980,
    "increasedecreaseinnumberthroughtransferoftreasuryshares": -17174,
    "increasedecreaseintrasurystockamountduetotransfer": 634751,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 16008,
    "treasurystockvalue": 591656,
    "numberofsharesoutstanding": 34165963,
    "increaseincapitalreserve": 388035,
    "reserveofexchangedifferencesontranslation": 115354088,
    "reserveofchangeinvalueoftimevalueofoptions": -27486,
    "subscriptionright": 1.1,
    "exercisepriceofoutstandingshareoptions2019": 13.21,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 72650,
    "numberofinstrumentsgrantedinsharebasedpaymentarrangement": 79935,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": -14267,
    "performancecriteria": 1.3,
    "numberofoutstandingshareoptions": 68305,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 408956,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 19,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": -1347,
    "numberofinstrumentsexercisableonreportingdate": 68305,
    "weightedaveragesharepriceshareoptionsgranted2019": 40.75,
    "strikepriceshareoptionsgranted": 44.91,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.4051,
    "weightedaveragefairvalueatmeasurementdateshareoptionsgranted": 30.43,
    "companyfactor": 1,
    "numberofperformanceshares": 45891,
    "percentageofsharesvested": 0.25,
    "targetachievement": 0.82,
    "sharebasedcompensationbysharebasedpaymentarrangementadjustmentduetoperformancecriteria": -2569,
    "performancetermofsharebasedprogramyears": 4,
    "liabilitiesfromsharebasedpaymenttransactions2011": 200000,
    "expensefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": -1074075,
    "paymentstoandonbehalfofemployees": 500000,
    "granted": 696622,
    "receivablesduefromassociates": 21000000,
    "numberofsharesissuedtorelatedparties": 2250,
    "numberofsharesissuedtorelatedpartiesduringperiodadditions": 3500,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 7847207000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 320248,
    "keymanagementpersonnelcompensationterminationbenefits": 320248000,
    "keymanagementpersonnelcompensationsharebasedpayment": 4600000,
    "keymanagementpersonnelcompensation": 9159782,
    "remunerationofsupervisoryboard": 104210,
    "performanceunrelatedcompensation": 2738488,
    "performancerelatedcompensation": 1821294,
    "compensationofformeremployees": 1400000,
    "adjustmentsfordecreaseincreaseinaccruedincomeotherthancontractassets": 3100000,
    "performanceshareunits": 1252,
    "numberofrestrictedsharesexercisableinsharebasedpaymentarrangement": 19842,
    "futureminimumleasespaymentsoflowvalueassetsandothershorttermleases": 3000,
    "futureminimumpaymentsperformanceshareandunitprograms": 200000,
    "othercommitment": 1098000,
    "contractualobligation": 1298000,
    "futurepaymentcommitmentsforclinicalstudies": 228400000,
    "milestonepayment": 236500000,
    "deferredincomefromobligationstoroyaltypharma": 866500000,
    "contingentliabilitiesincurredinrelationtointerestsinassociates": 223800000,
    "currentinvestments": 14622000,
    "investmentsfixedtermdeposits": 490201000,
    "otherreceivablesfinancialassets": 12852000,
    "thereofforwardexchangecontractsusedforhedging": 9832000,
    "otherreceivablesthereofnonfinancialassets": 3020000,
    "currentfinancialassets": 1008237000,
    "longtermrestrictedcash": 1324000,
    "othercurrentnonfinancialassets": 7405000,
    "noncurrentfinancialassets": 1324000,
    "tradeandothercurrentpayables": 38579000,
    "othernonfinancialliabilities": 118691000,
    "currentconvertiblebond": -2031000,
    "currentfinancialliabilitiesfromcollaboration": -2514000,
    "noncurrentconvertiblebond": -291647000,
    "noncurrentfinancialliabilitiesfromcollaboration": -217826000,
    "currentfinancialassetsatfairvaluethroughprofitorloss": 24454000,
    "currentfinancialassetsatamortisedcost": 985107000,
    "currentfinancialliabilitiesatamortisedcost": 2053071000,
    "percentageofvotingequityinterestsacquired": 17.2,
    "equitymethodinvestmentaccountedindomesticcurrency": 92948,
    "gainlossonfinancialinstruments": 7051000,
    "interestincomeforfinancialassetsmeasuredatamortisedcost": 4618000,
    "interestexpensesonfinancialassetsatamortisedcost": -1580000,
    "interestexpenseonotherfinancialliabilities": 102144000,
    "grossgainslossesonfinancialinstruments": -99106000,
    "impairmentlossonfinancialasset": -697000,
    "unusedprovisionamountsreversed": 685000,
    "increasedecreaseinimpairmentlossforcreditriskrecognizedinprofitorloss": -697000,
    "internalcreditrating": "low",
    "descriptionofrecognitionofexpectedcreditlossprovision": "Expected Twelve-Month Loss",
    "grosscarryingamountoffinancialassets": 402353000,
    "maximumexposuretocreditriskondebtinstruments": 14600000,
    "maximumexposuretocreditriskonfinancialguarantees": 1300000,
    "convertiblebondsduetorelatedparties": 2031000,
    "financialliabilitiesfromcollaboration": 2588000,
    "foreigncurrencyriskexposurenet": -225254000,
    "foreignexchangesensitivityanalysis": 15600000,
    "equitycapitalpercentage": 0.066,
    "liabilitiescapitalpercentage": 0.934,
    "liabilitiesarisingfromfinancingactivities": -45781000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 4446000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": -6224000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": -368000,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": 354390000,
    "noncurrentassetsexcludingdeferredtaxassets": 142700000,
    "additionspropertyplantandequipmentandintangibleassets": 15200000,
    "upfrontpayment": 15000000,
    "paymentsfromhibio": 500000000
  },
  {
    "date": "2021-12-31",
    "symbol": "MOR",
    "period": "FY",
    "documenttype": "20-F",
    "documentregistrationstatement": "£",
    "documentannualreport": "true",
    "currentfiscalyearenddate": "December 31",
    "documenttransitionreport": "£",
    "documentshellcompanyreport": "£",
    "documentperiodenddate": "December 31, 2021",
    "entityfilenumber": "001-38455",
    "entityregistrantname": "MorphoSys AG",
    "entityincorporationstatecountrycode": "Germany",
    "contactpersonnelname": "Sung Lee",
    "entityaddressaddressline1": "Semmelweisstrasse 7",
    "entityaddresspostalzipcode": 82152,
    "entityaddresscityortown": "Planegg",
    "entityaddresscountry": "Germany",
    "cityareacode": 49,
    "localphonenumber": "89-89927-0",
    "security12btitle": "Ordinary Shares, no-par-value*",
    "tradingsymbol": "MOR",
    "securityexchangename": "The NASDAQ Stock Market LLC",
    "entitycommonstocksharesoutstanding": 34231943,
    "entitywellknownseasonedissuer": "Yes",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Large accelerated filer",
    "entityemerginggrowthcompany": "£",
    "icfrauditorattestationflag": "true",
    "entityshellcompany": "No",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entitycentralindexkey": 1340243,
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "PricewaterhouseCoopers GmbH",
    "auditorfirmid": 1275,
    "auditorlocation": "Munich, Germany",
    "revenuefromsaleofgoods": 66860637,
    "revenuefromroyalties": 65576120,
    "licensesmilestonesandother": 47175087,
    "revenue": 62900000,
    "costofsales": 28000,
    "grossprofit": 147417139,
    "researchanddevelopmentexpense": 4116000,
    "sellingexpense": 5667000,
    "generalandadministrativeexpense": 2242000,
    "impairmentlossrecognisedinprofitorlossgoodwill": 230700000,
    "operatingexpense": 655760744,
    "profitlossfromoperatingactivities": -508343605,
    "otherincome": 8189829,
    "otherexpensebynature": 6368762,
    "financeincome": 96612146,
    "financecosts": 181456484,
    "impairmentlossreversalofimpairmentlossrecognisedonfinancialassets": 316000,
    "incometaxexpensecontinuingoperations": -76590860,
    "profitloss": -514460016,
    "earningspersharebasicanddiluted": -15.4,
    "basicearningslosspershare": -15.4,
    "dilutedearningslosspershare": -15.4,
    "weightedaveragenumberofequitysharesusedincomputingearningspersharebasicanddiluted": 33401069,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 50546172,
    "othercomprehensiveincome": 50546172,
    "comprehensiveincome": -514460016,
    "cashandcashequivalents": 106188000,
    "financialassetsatfairvaluethroughprofitorloss": 96192000,
    "tradereceivablesandcontractassets": 75911054,
    "currentfinancialassetsfromcollaboration": 16730000,
    "currentincometaxreceivables": 1089078,
    "othercurrentreceivables": 2226912,
    "inventories": 20755187,
    "currentprepaymentsandothercurrentassets": 39323437,
    "currentassets": 1132969950,
    "propertyplantandequipment": 3148000,
    "rightofuseassets": 1188000,
    "intangibleassetsotherthangoodwill": 838322389,
    "goodwill": 564700000,
    "deferredtaxassets": 190261000,
    "noncurrentprepaidexpensesandotherassets": 13250634,
    "noncurrentassets": 1423284266,
    "assets": 2556254216,
    "accountspayableandaccrualscurrent": 339000,
    "currentleaseliabilities": 3238111,
    "currenttaxprovisions": 528217,
    "otherprovisions": 2549397,
    "currentcontractliabilities": 223862,
    "currentportionoflongtermborrowings": 422945,
    "currentportionoffinancialliabilitiesfromcollaborations": 1097295,
    "currentportionoffinancialliabilitiesfromfuturepaymentstoroyaltypharma": 1646860000,
    "currentliabilities": 284538386,
    "noncurrentleaseliabilities": 39345777,
    "otherlongtermprovisions": 1576379,
    "noncurrentcontractliabilities": 28731,
    "netdeferredtaxliabilities": 22065419,
    "longtermborrowings": 282784505,
    "financialliabilitiesfromcollaborationsnetofcurrentportion": 513264290,
    "financialliabilitiesfromfuturepaymentstoroyaltypharmalongterm": -1367365000,
    "noncurrentliabilities": 2026839887,
    "liabilities": 2311378273,
    "treasuryshares": 3085054,
    "issuedcapital": 34231943,
    "additionalpaidincapital": 833320689,
    "reserveofmiscellaneousothercomprehensiveincome": 52757591,
    "retainedearnings": -672349226,
    "equity": -672349226,
    "equityandliabilities": 2556254216,
    "numberoftreasuryshares": 83154,
    "equitybeginningbalanceshares": 131414,
    "issueofequity": 84638605,
    "issueofequityshares": 1337552,
    "increasedecreasethroughsharebasedpaymenttransactions": 2587931,
    "exerciseofconvertiblebondsissued": 241234,
    "exerciseofconvertiblebondsissuedshares": 4345,
    "saleorissueoftreasuryshares": -1783690,
    "saleorissueoftreasurysharesshares": -48260,
    "equityendingbalanceshares": 83154,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 235916060,
    "adjustmentsfordepreciationandamortisationexpense": 10090958,
    "adjustmentinnetgainlossonsalesoffinancialassetsatfairvaluethroughprofitorloss": -3376711,
    "adjustmentinimpairmentlossreversalofimpairmentlossrecognisedonfinancialassets": 316000,
    "adjustmentsfordecreaseincreaseinderivativefinancialassets": 3495651,
    "noncasheffectivenetchangesinfinancialassetsorfinancialliabilitiesfromcollaborations": 16007722,
    "noncasheffectivenetchangeinfinancialliabilitiesfromfuturepaymentstoroyaltypharma": -42766283,
    "noncasheffectivechangeoffinanicalliabilitiesaytamortizedcost": 12055784,
    "adjustmentsforsharebasedpayments": 2585426,
    "adjustmentsforincometaxexpense": -76590860,
    "adjustmentsfordecreaseincreaseintradeaccountsreceivableandcontractassets": 10532824,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -30348390,
    "adjustmentsfordecreaseincreaseinaccountspayableandaccrualstaxprovisionsandotherprovisions": -90815610,
    "adjustmentsforincreasedecreaseindeferredincomeincludingcontractliabilities": -2363139,
    "incometaxespaidclassifiedasoperatingactivities": 64609622,
    "cashflowsfromusedinoperatingactivities": -481445084,
    "purchaseofavailableforsalefinancialassets": 2188341595,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 2591975683,
    "paymentsfromderivativefinancialinstruments": 3495651,
    "acquisitionsnetofcashacquired": 1206609948,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 3810210,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 22345955,
    "interestreceivedclassifiedasinvestingactivities": 1617544,
    "cashflowsfromusedininvestingactivities": -831010132,
    "proceedsfromissuingshares": 84730022,
    "paymentsforshareissuecosts": 91417,
    "proceedsinconnectionwithconvertiblebondsgrantedtorelatedparties": 241234,
    "proceedsfromnoncurrentborrowings": 40004094,
    "cashreceiptsfromcontractsforfuturepaymentstoroyaltypharma": -1206706749,
    "cashpaymentsforcostsinconnectionwithcontractswithroyaltypharma": 796003,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 3126348,
    "interestpaidclassifiedasfinancingactivities": 4744851,
    "cashflowsfromusedinfinancingactivities": 1322923480,
    "effectofexchangeratechangesoncashandcashequivalents": 2985312,
    "increasedecreaseincashandcashequivalents": 13453576,
    "mandatoryapplicationforfinancialyearsstartingdate": "01/01/2022",
    "adoptedbytheeuropeanunionstatus": "yes",
    "impactonmorphosysstatus": "none",
    "possibleimpactonmorphosysstatus": "none",
    "basisofconsolidationbeginningdate": "07/02/2018",
    "descriptionofusefullifepropertyplantandequipment": "10 years",
    "depreciationratepropertyplantandequipment": 0.1,
    "descriptionofusefullifeintangibleassetsotherthangoodwill": "3 to 5 years",
    "percentageofacquiredsharesinconstellation": 0.11,
    "profitlossofacquiree": -645700000,
    "acquisitionrelatedcostsfortransactionrecognisedseparatelyfromacquisitionofassetsandassumptionofliabilitiesinbusinesscombination": 19200000,
    "fairvalue": 719400000,
    "retentionbonusesconstellation": 5700000,
    "severancepaymentsconstellation": 7300000,
    "milestonepaymentconstellation": 7400000,
    "revenuefromperformanceobligationssatisfiedorpartiallysatisfiedinpreviousperiods": 85500000,
    "employeebenefitsexpense": 173677000,
    "postemploymentbenefitexpensedefinedcontributionplans": 2800000,
    "numberofemployees": 732,
    "averagenumberofemployees": 678,
    "netforeignexchangegain": 7640000,
    "revenuefromgovernmentgrants": 5000,
    "miscellaneousoperatingincome": 545000,
    "netforeignexchangeloss": 5944000,
    "miscellaneousexpenses": 425000,
    "foreigncurrencygainsfromfinancialassetsfromcollaborations": 18782000,
    "gainsonchangeinfairvalueofderivatives": 15231000,
    "adjustmentsforfinanceincome": 61876000,
    "revenuefrominterest": 723000,
    "foreigncurrencylossesfromfinancialliabilitiesfromcollaborations": 46297000,
    "lossesonchangeinfairvalueofderivatives": 4247000,
    "interestexpenseforfinancialliabilitiesnotatfairvaluethroughprofitorloss": 62252000,
    "adjustmentsforfinancecosts": 64846000,
    "interestexpense": 2415000,
    "interestexpenseonleaseliabilities": 1170000,
    "bankandsimilarcharges": 242000,
    "currenttaxexpenseincome": -1172000,
    "deferredtaxexpenseincome": -75419000,
    "adjustmentsforcurrenttaxofpriorperiod": -96000,
    "corporatetaxrate": 0.15,
    "solidaritysurchargerate": 0.055,
    "effectivetradetaxrate": 0.1085,
    "applicabletaxrate": 0.26675,
    "federalcorporateincometaxrate": 0.21,
    "stateincometaxrate": 0.045599999999999995,
    "percentageofincometaxable": 0.2556,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": -34800000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 75419000,
    "taxlossesfromconstellation": 563697000,
    "currentyeartaxlossescarryforwards": 138257000,
    "foreigncurrencytranslation": 22795000,
    "reclassificationtotemporarydifference": 724749000,
    "expiryordeconsolidation": 186945000,
    "utilizationoftaxlosses": -7817000,
    "taxlossescarryforwards": 179128000,
    "accountingprofit": 591051000,
    "taxexpenseincomeatapplicabletaxrate": -157663000,
    "taxeffectofsharebasedcompensation": 547000,
    "taxeffectsofpermanentdifferences": -58971000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 1992000,
    "taxeffectfromnonrecognitionofdeferredtaxassetsontemporarydifferences1": 8117000,
    "taxeffectfromnonrecognitionofdeferredtaxassetsoncurrentyeartaxlosses1": 7817000,
    "taxeffectofforeigntaxrates": 3721000,
    "taxeffectofprioryearadjustments": -96000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 3000,
    "averageeffectivetaxrate": 0.13,
    "deferredtaxliabilities": 22065000,
    "taxlossesrelativetoustaxgroup": 69900000,
    "deferredtaxassetsontemporarydifferencesnotcapitalized": 8100000,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": -38688000,
    "deferredtaxliabilitiesrecognisedasofacquisitiondate": 38700000,
    "deferredtaxassetsrecognisedasofacquisitiondate": 145900000,
    "deferredtaxitemsrecognizedagainstequity": 12700000,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -514460016,
    "weightedaverageshares": 33401069,
    "adjustedweightedaverageshares": 33401069,
    "numberofstockoptionsunvested": 41632,
    "numberofrestrictedstockunitsunvested": 108576,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 2475437,
    "cash": 123248000,
    "availableforsalefinancialassetsmaturity": "daily",
    "availableforsalefinancialassetscost": 8874000,
    "grossunrealizedgainsonfinancialassetsavailableforsale": 1000,
    "currentfinancialassetsavailableforsale": 8875000,
    "currentloansandreceivables": 844812000,
    "grossunrealizedgainsonloansandreceivables": -2025000,
    "grossunrealizedlossesonloansandreceivables": 185000,
    "loansandreceivablesmaturity": "4 to 12 months",
    "netgainfromdisposalofavailableforsalefinancialassets": 600000,
    "netgainfromdisposaloffinancialassetsatfairvaluethroughprofitandloss": -1700000,
    "currenttradereceivables": 42754000,
    "accountsreceivablenoninterestbearingpaymentterms": "between 30 and 180 days",
    "receivablesfromcontractswithcustomers": 38500000,
    "percentageofaccountsreceivable": 0.09,
    "otherreceivables": 1100000,
    "currentrawmaterialsandcurrentproductionsupplies": 12100000,
    "workinprogress": 4099999.9999999995,
    "finishedgoods": 4500000,
    "prepaidexpensesandothercurrentassetsconsistedofcombinationcompounds": 15945000,
    "receivablesfrominputtaxsurplus": 6563000,
    "currentprepaidexpenses": 1304000,
    "othercurrentprepayments": 13787000,
    "prepaidexpensesandothercurrentassets": 39323000,
    "noncurrentprepaidexpenses": 9192000,
    "othernoncurrentassets": 4059000,
    "impairmentoncombinationcompounds": 3500000,
    "noncurrentrestrictedcashandcashequivalents": 3800000,
    "restrictedcashascollateralforcreditcards": 200000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 3701000,
    "acquisitionsthroughbusinesscombinationspropertyplantandequipment": 1622000,
    "disposalspropertyplantandequipment": -1831000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -835119,
    "depreciationpropertyplantandequipment": 2843000,
    "impairmentlossrecognisedinprofitorlosspropertyplantandequipment": 1572000,
    "depreciationexpense": 4370000,
    "leaseliabilities": 42584000,
    "additionstorightofuseassets": 1385000,
    "additionforleaseliabilities": 316000,
    "depreciationrightofuseassets": 3688000,
    "leasepayments": 4286000,
    "disposalofrightofuseassets": -51000,
    "disposalsforleaseliabilities": -173000,
    "foreignexchangegainlossrightofuseassets": 421000,
    "foreignexchangegainlossleaseliabilities": 538000,
    "depreciationrightofuseassetsaftercurrencytranslation": 1711000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 1553000,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 17000,
    "impactonprofitorlossduetoadoptionoflease": 6375000,
    "netleaseliabilities": 49565,
    "intangibleassetsandgoodwill": 838322000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 22496000,
    "acquisitionsthroughbusinesscombinationsintangibleassetsotherthangoodwill": 719415000,
    "disposalsintangibleassetsotherthangoodwill": -4755000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 30679000,
    "amortizationchargefortheyear": 3623000,
    "impairmentlossofintangibleassetsandgoodwill": 13000,
    "milestonepaymentswerecapitalized": 10400000,
    "betafactor": 1.7,
    "weightedaveragecostofcapitalbeforetaxpercentage": 0.141,
    "capitalizedrdprogram": 2000000,
    "increaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsassets": -800000,
    "decreaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsassets": 800000,
    "descriptionofgrowthrateusedtoextrapolatecashflowprojections": 0.01,
    "changeinwaccbeforetax": 0.01,
    "tradeaccountspayable": 73787000,
    "accruedliabilities": 113055000,
    "othercurrentliabilities": 1235000,
    "accountspayableandaccruedexpensescurrent": 188077000,
    "externallaboratoryservices": 65026000,
    "accruedpersonnelexpensesforpaymentstoemployeesandmanagement": 29666000,
    "accruedoutstandingexpense": 12515000,
    "accruedrevenuedeductionsfromproductsales": 1998000,
    "expensesforlegaladvice": 169000,
    "auditfeesandotherauditrelatedcosts": -2258000,
    "licensepayments": 2978000,
    "accruedliabiitycurrent": 113055000,
    "auditfees": -2141000,
    "otherauditrelatedcosts": -116000,
    "otherfeesandotherservices": -2000,
    "taxliabilitiescurrentandnoncurrent": 528000,
    "currentprovisions": 2549000,
    "noncurrentprovisions": 1577000,
    "taxprovisionsandcurrentandnoncurrentotherprovisions": 66007000,
    "contractliabilities": 253000,
    "contractliabilitiesprepaymentsreceived": 4323000,
    "revenuethatwasincludedincontractliabilitybalanceatbeginningofperiod": 2544000,
    "revenuerecognizedforreceivedprepaymentsandservicesperformed": -4142000,
    "nominalamountbond": 1,
    "issueofconvertibleinstruments": 49200000,
    "liabilitycomponentofconvertiblebond": 270700000,
    "notionalamount": 100000,
    "numberofsharesissued": 3250,
    "debtcouponrate": 0.00625,
    "debtconversionprice": 131.29,
    "debtinstrumentconvertiblenumberofequityinstruments": 2475436,
    "redemptionpercentageofdebtinstrumentwhenmarketpriceofsharesfalldown": 1.3,
    "redemptionpercentagebasedonoutstandingnominalamount": 0.2,
    "proportionofvotingpowerheldinsubsidiary": 0.3,
    "interestexpenseondebtinstrumentsissued": 325000000,
    "financialassetsatfairvalue": 16730000,
    "decreasethroughderecognitionfinancialassets": 40004000,
    "revenuerecognitionmilestonemethodrevenuerecognized": 971200000,
    "percentageonshareofprofitlossofassociatesandjointventures": 0.5,
    "financialassets": 1085053000,
    "percentageofsharesindevelopmentcost": 0.45,
    "percentageoffuturedevelopmentcostsforclinicaltrials": 1,
    "currentfinancialliabilities": 277998000,
    "noncurrentfinancialliabilities": 1963824000,
    "changeinexpectedsalesrevenues": 0.01,
    "changeinfairvalue": 17300000,
    "increaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": -14400000,
    "decreaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": 14800000,
    "percentageoffutureroyalties": 0.8,
    "increasedecreaseinnumberofsharesoutstanding": 1337552,
    "weightedaverageshareprice2019": 44.91,
    "transactioncostsonfinancialliabilities": 900000,
    "impliedinterestrate": 0.14,
    "marketinterestrate": 0.065,
    "liabilityfromsaleofroyalties": 1193300000,
    "increasedecreaseinnumberofordinarysharesissued": 1341897,
    "numberofstockoptionsexcercised": 4345,
    "noparvaluepershare": 1,
    "numberofsharesauthorised": 7287025,
    "numberofsharesofconditionalcapital": 7816101,
    "notionalamountpercent": -0.1,
    "increasedecreaseinnumberthroughtransferoftreasuryshares": -48260,
    "increasedecreaseintrasurystockamountduetotransfer": 1783690,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 4345,
    "treasurystockvalue": 87558,
    "numberofsharesoutstanding": 34148789,
    "debtrelatedtransactioncost": 91417,
    "increaseincapitalreserve": 84342183,
    "reserveofexchangedifferencesontranslation": 52785077,
    "reserveofchangeinvalueoftimevalueofoptions": -27486,
    "subscriptionright": 2,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 16996,
    "numberofinstrumentsgrantedinsharebasedpaymentarrangement": 66497,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 711223,
    "exercisepriceofoutstandingshareoptions2019": 33.35,
    "numberofoutstandingshareoptions": 115099,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 323534,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 29941,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": -1799,
    "weightedaveragesharepriceshareoptionsgranted2019": 40.75,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.2217,
    "performancetermofsharebasedprogramyears": 4,
    "weightedaveragefairvalueatmeasurementdateshareoptionsgranted": 16.67,
    "performancecriteria": 1.25,
    "companyfactor": 2,
    "numberofperformanceshares": 39718,
    "percentageofsharesvested": 0.33299999999999996,
    "sharebasedcompensationbysharebasedpaymentarrangementadjustmentduetoperformancecriteria": 16053,
    "expensefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 117395,
    "performanceshareunits": 1865,
    "granted": 11209,
    "targetachievement": 1,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": -4143,
    "paymentstoandonbehalfofemployees": 500000,
    "liabilitiesfromsharebasedpaymenttransactions2011": 500000,
    "excerciseprice": 44.91,
    "numberofsharesissuedtorelatedparties": 7563,
    "numberofsharesissuedtorelatedpartiesduringperiodadditions": 5963,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 3105,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 7336167000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 443372000,
    "keymanagementpersonnelcompensationterminationbenefits": 806297000,
    "keymanagementpersonnelcompensationsharebasedpayment": 4278500000,
    "keymanagementpersonnelcompensation": 12864336000,
    "remunerationofsupervisoryboard": 625872,
    "performanceunrelatedcompensation": 3759850,
    "performancerelatedcompensation": 2680000,
    "liabilityforseverancepayment": 806296,
    "compensationofformeremployees": 4600000,
    "adjustmentsfordecreaseincreaseinaccruedincomeotherthancontractassets": 3300000,
    "futureminimumleasespaymentsoflowvalueassetsandothershorttermleases": 33000,
    "futureminimumpaymentsperformanceshareandunitprograms": 5105000,
    "othercommitment": 11464000,
    "contractualobligation": 16602000,
    "futurepaymentcommitmentsforclinicalstudies": 236500000,
    "milestonepayment": 236500000,
    "deferredincomefromobligationstoroyaltypharma": 988900000,
    "contingentliabilitiesincurredinrelationtointerestsinassociates": 223100000,
    "increasedecreaseindeferredtaxliabilityasset": -40600000,
    "currentinvestments": 8875000,
    "investmentsfixedtermdeposits": 844811000,
    "otherreceivablesfinancialassets": 2227000,
    "otherreceivablesthereofnonfinancialassets": 2227000,
    "currentfinancialassets": 1071802000,
    "longtermrestrictedcash": 4059000,
    "othercurrentnonfinancialassets": 9192000,
    "noncurrentfinancialassets": 13251000,
    "tradeandothercurrentpayables": 73787000,
    "othernonfinancialliabilities": 114290000,
    "currentconvertiblebond": -423000,
    "currentfinancialliabilitiesfromcollaboration": -1097000,
    "noncurrentconvertiblebond": -304025000,
    "noncurrentfinancialliabilitiesfromcollaboration": -514169000,
    "financialliabilities": 2241822000,
    "currentfinancialassetsatfairvaluethroughprofitorloss": 25605000,
    "currentfinancialassetsatamortisedcost": 1048029000,
    "currentfinancialliabilitiesatamortisedcost": 2127532000,
    "percentageofvotingequityinterestsacquired": 0.172,
    "equitymethodinvestmentaccountedindomesticcurrency": -681809,
    "gainlossonfinancialinstruments": -83761000,
    "interestincomeforfinancialassetsmeasuredatamortisedcost": 723000,
    "interestexpensesonfinancialassetsatamortisedcost": -2415000,
    "interestexpenseonotherfinancialliabilities": 62252000,
    "grossgainslossesonfinancialinstruments": -63944000,
    "impairmentlossonfinancialasset": -1045000,
    "unusedprovisionamountsreversed": 1425000,
    "increasedecreaseinimpairmentlossforcreditriskrecognizedinprofitorloss": -1045000,
    "internalcreditrating": "low",
    "descriptionofrecognitionofexpectedcreditlossprovision": "Lifetime Expected Credit Losses",
    "grosscarryingamountoffinancialassets": 76270000,
    "maximumexposuretocreditriskondebtinstruments": 25600000,
    "maximumexposuretocreditriskonfinancialguarantees": 4099999.9999999995,
    "convertiblebondsduetorelatedparties": 333125000,
    "financialliabilitiesfromcollaboration": -514362000,
    "futurecashoutflowfromfinancialliabilitiesfromroyaltypharma": 1500000,
    "financialassetsfromcollaboration": 16730000,
    "currentrestrictedcashandcashequivalents": 3397000,
    "foreigncurrencyriskexposurenet": -339000,
    "foreignexchangesensitivityanalysis": -800000,
    "equitycapitalpercentage": 0.096,
    "liabilitiescapitalpercentage": 0.904,
    "liabilitiesarisingfromfinancingactivities": -2096329000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": -1199594000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": -316000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": -47383000,
    "depreciationandamortisationexpense": 18877000,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": -2970000,
    "noncurrentassetsexcludingdeferredtaxassets": 1103800000,
    "additionspropertyplantandequipmentandintangibleassets": 1700000
  },
  {
    "date": "2020-12-31",
    "symbol": "MOR",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MOR",
    "documentannualreport": "true",
    "entityregistrantname": "MorphoSys AG",
    "entitycentralindexkey": 1340243,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "001-38455",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Large Accelerated Filer",
    "entityshellcompany": "false",
    "documentshellcompanyreport": "false",
    "entityemerginggrowthcompany": "false",
    "entitycommonstocksharesoutstanding": 32890046,
    "security12btitle": "Ordinary Shares, no par value",
    "securityexchangename": "NASDAQ",
    "entityaddresscountry": "DE",
    "entityinteractivedatacurrent": "Yes",
    "documentregistrationstatement": "false",
    "documenttransitionreport": "false",
    "icfrauditorattestationflag": "true",
    "revenue": 49068000,
    "costofsales": 2251000,
    "researchanddevelopmentexpense": -3338000,
    "sellingexpense": 700000,
    "generalandadministrativeexpense": 4084000,
    "operatingexpense": 32945000,
    "otherincome": 5199000,
    "otherexpensebynature": 5175000,
    "profitlossfromoperatingactivities": 27361198,
    "financeincome": 10052000,
    "financecosts": 50771000,
    "impairmentlossreversalofimpairmentlossrecognisedonfinancialassets": -702000,
    "incometaxexpensecontinuingoperations": -75398566,
    "profitloss": 97890576,
    "basicearningslosspershare": 3.01,
    "dilutedearningslosspershare": 2.97,
    "weightedaveragenumberofequitysharesusedincomputingearningspersharebasicanddiluted": 32525644,
    "weightedaveragenumberofsharesoutstandingbasic": 32525644,
    "weightedaveragenumberofsharesoutstandingdiluted": 33167852,
    "othercomprehensiveincomenetoftaxgainslossesfrominvestmentsinequityinstruments": 1260132,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 2247005,
    "othercomprehensiveincome": 3507137,
    "comprehensiveincome": 97890576,
    "cashandcashequivalents": 109795000,
    "financialassetsatfairvaluethroughprofitorloss": 10458000,
    "currentfinancialassetsatamortisedcost": 649713000,
    "tradereceivablesandcontractassets": 83354276,
    "financialassetsfromcollaboration": 42870499,
    "currentincometaxreceivables": 401826,
    "othercurrentreceivables": 2159475,
    "inventories": 9962657,
    "currentprepaymentsandothercurrentassets": 20621493,
    "currentassets": 1054336000,
    "propertyplantandequipment": 3117000,
    "rightofuseassets": 196000,
    "copyrightspatentsandotherindustrialpropertyrightsserviceandoperatingrights": 1937856,
    "licencesandfranchises": 11835619,
    "licensesformarketedproducts": 55485886,
    "computersoftware": 115788,
    "goodwill": 3700000,
    "noncurrentfinancialassetsatamortisedcost": 197749000,
    "deferredtaxassets": 1328,
    "noncurrentprepaidexpensesandotherassets": 1567259,
    "noncurrentassets": 341784000,
    "assets": 1396120000,
    "accountspayableandaccrualscurrent": 128554000,
    "currentleaseliabilities": 3056000,
    "currenttaxprovisions": 65727675,
    "otherprovisions": 300000,
    "currentcontractliabilities": 2543903,
    "currentportionoflongtermborrowings": 422945,
    "currentportionoffinancialliabilitiesfromcollaborations": 154895,
    "currentliabilities": 90919000,
    "noncurrentleaseliabilities": 41964000,
    "noncurrentprovisions": 1527756,
    "noncurrentcontractliabilities": 71830,
    "netdeferredtaxliabilities": 5057465,
    "longtermborrowings": 272759970,
    "financialliabilitiesfromcollaborationsnetofcurrentportion": 516350960,
    "noncurrentliabilities": 288454000,
    "liabilities": 1038191003,
    "issuedcapital": 32890046,
    "treasuryshares": 4868744,
    "additionalpaidincapital": 748978506,
    "reserveofmiscellaneousothercomprehensiveincome": 2211419,
    "retainedearnings": -157889210,
    "equity": -157889210,
    "equityandliabilities": 1000695000,
    "numberofsharesissued": 3250,
    "numberofsharesoutstanding": 32758632,
    "numberoftreasurysharesissued": 131414,
    "equitybeginningbalanceshares": 225800,
    "issueofequity": 80498098,
    "issueofequityshares": 907441,
    "increasedecreasethroughsharebasedpaymenttransactions": 7455761,
    "equitycomponentoftheconvertibledebtvalue": 36483050,
    "exerciseofconvertiblebondsissued": 785623,
    "exerciseofconvertiblebondsissuedshares": 24647,
    "saleorissueoftreasuryshares": -3488506,
    "saleorissueoftreasurysharesshares": -94386,
    "equityendingbalanceshares": 131414,
    "shareissuerelatedcost": 100370,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 16480272,
    "adjustmentsfordepreciationandamortisationexpense": 8329559,
    "adjustmentinnetgainlossonsalesoffinancialassetsatfairvaluethroughprofitorloss": 13401584,
    "adjustmentinnetgainlossonsalesoffinancialassetsatamortizedcost": -8378845,
    "adjustmentinimpairmentlossreversalofimpairmentlossrecognisedonfinancialassets": -702000,
    "adjustmentsfordecreaseincreaseinderivativefinancialassets": 4252171,
    "noncasheffectivenetchangesinfinancialassetsorfinancialliabilitiesfromcollaborations": 36551618,
    "noncasheffectivechangeoffinanicalliabilitiesaytamortizedcost": 2453561,
    "reversalofimpairmentlossrecognisedinprofitorloss": 13270968,
    "adjustmentsforgainlossondisposalofinvestmentsinsubsidiariesjointventuresandassociates": -379173,
    "increasedecreasethroughcumulativecatchupadjustmentstorevenuecontractliabilities": 12500264,
    "adjustmentsforsharebasedpayments": 8955307,
    "adjustmentsforincometaxexpense": -75398566,
    "adjustmentsfordecreaseincreaseintradeaccountsreceivableandcontractassets": -69619751,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -8485396,
    "adjustmentsfordecreaseincreaseinaccountspayableandaccrualstaxprovisionsandotherprovisions": 77505284,
    "adjustmentsforincreasedecreaseindeferredincome": 13430268,
    "incometaxespaidclassifiedasoperatingactivities": 303974,
    "cashflowsfromusedinoperatingactivities": 35269717,
    "purchaseofavailableforsalefinancialassets": 495970604,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 214209301,
    "purchaseoffinancialinstrumentsclassifiedasinvestingactivities": 1249729925,
    "proceedsfromsalesormaturityoffinancialinstrumentsclassifiedasinvestingactivities": 686568082,
    "proceedsfromderivativefinancialinstruments": -3855905,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 4455323,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 44881207,
    "purchaseoffinancialassetsatfairvaluethroughothercomprehensiveincome": -14804287,
    "cashflowsfromlosingcontrolofsubsidiariesorotherbusinessesclassifiedasinvestingactivities": 2477760,
    "interestreceivedclassifiedasinvestingactivities": 1210668,
    "cashflowsfromusedininvestingactivities": -879622866,
    "proceedsfromissuingshares": 80598468,
    "paymentsforshareissuecosts": 100370,
    "proceedsinconnectionwithconvertiblebondsgrantedtorelatedparties": 773300,
    "proceedsfromnoncurrentborrowings": 510186974,
    "proceedsfromissueofbondsnotesanddebentures": 325000000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 3918000,
    "interestpaidclassifiedasfinancingactivities": 1431487,
    "cashflowsfromusedinfinancingactivities": 907186124,
    "effectofexchangeratechangesoncashandcashequivalents": 3397655,
    "increasedecreaseincashandcashequivalents": 66230630,
    "disposalofcashandcashequivalentsduetodeconsolidationofsubsidaries": -750000,
    "maximumexposuretocreditriskondebtinstruments": 330800000,
    "receivablesfromcontractswithcustomers": 50100000,
    "percentageofaccountsreceivable": 0.6,
    "percentageofrevenuefromtopcustomer": 0.01,
    "maximumexposuretocreditriskonfinancialguarantees": 1400000,
    "increasedecreaseinincomeduetochangeinforeignexchangerates": 96200000,
    "increaseinvariableinterestrate": 0.005,
    "decreaseinvariableinterestrate": 0.005,
    "increaseinnetearnings": 1200000,
    "decreaseinnetearnings": 1400000,
    "descriptionofcreditdefaultswaps": "The Group currently classifies an increase in credit risk on debt instruments as significant when the premium on a counterparty credit default swap has increased by 100 basis points since the initial recognition of the instrument (Level 2).",
    "equityratiopercentage": 0.374,
    "descriptionofusefullifepropertyplantandequipment": "3 - 5 years",
    "notionalamount": 325000000,
    "antidilutivesharesofinstrumentswithpotentialfuturedilutiveeffectincludedincalculationofdilutedearningsshares": 67964,
    "antidilutivesharesofrestrictedstockinstrumentswithpotentialfuturedilutiveeffectincludedincalculationofdilutedearningsshares": 58811,
    "antidilutivesharesofconvertibledebtinstrumentswithpotentialfuturedilutiveeffectincludedincalculationofdilutedearningsshares": 515433,
    "periodforwhichaccountsreceivableshallbeoverdueforrecordingimpairment": "P2Y",
    "mandatoryapplicationforfinancialyearsstartingdate": "01/01/2022",
    "adoptedbytheeuropeanunionstatus": "no",
    "impactonmorphosysstatus": "none",
    "possibleimpactonmorphosysstatus": "none",
    "purchasedateofshares": "July 2018",
    "basisofconsolidationbeginningdate": "07/02/2018",
    "impairmentlossonfinancialasset": -1425000,
    "unusedprovisionamountsreversed": 379000,
    "increasedecreaseinimpairmentlossforcreditriskrecognizedinprofitorloss": -1425000,
    "internalcreditrating": "low",
    "descriptionofrecognitionofexpectedcreditlossprovision": "Lifetime Expected Credit Losses",
    "grosscarryingamountoffinancialassets": 83778000,
    "impairmentlossonfinancialassets": 702000,
    "financialassets": 52600000,
    "averageimpairmentrate": 0.005,
    "currenttradereceivables": 50100000,
    "tradeaccountspayable": 47558635,
    "convertiblebondsduetorelatedparties": 2031250,
    "financialliabilitiesfromcollaboration": -516505855,
    "financialassetsatamortisedcost": 57326015,
    "currentrestrictedcashandcashequivalents": 1384000,
    "foreigncurrencyriskexposurenet": -52305,
    "currentfinancialassetsfromcollaboration": 42870000,
    "otherreceivables": 1200000,
    "currentfinancialassets": 1175829000,
    "othercurrentnonfinancialassets": 183000,
    "noncurrentfinancialassets": 198155000,
    "currentconvertiblebond": -423000,
    "currentfinancialliabilitiesfromcollaboration": -155000,
    "currentfinancialliabilities": 633800000,
    "noncurrentconvertiblebond": -334124000,
    "noncurrentfinancialliabilitiesfromcollaboration": -617178000,
    "noncurrentfinancialliabilities": 633800000,
    "financialliabilities": 963263000,
    "equitycapitalpercentage": 0.374,
    "liabilitiescapitalpercentage": 0.626,
    "liabilitiesarisingfromfinancingactivities": 42870000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 32413000,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": -5286000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": -5549000,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": 16007000,
    "changesinequity": 49217000,
    "depreciationratepropertyplantandequipment": 0.1,
    "amortisationrateintangibleassetsotherthangoodwill": 0.2,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P5Y",
    "descriptionandcarryingamountofintangibleassetswithindefiniteusefullife": "Not yet amortized,Impairment Only",
    "descriptionofamortisationmethodforgoodwill": "Impairment Only",
    "segmentresult": 17951000,
    "segmentprofitlossfromoperatingactivities": 27361000,
    "profitlossbeforetax": 22492000,
    "additionspropertyplantandequipmentandintangibleassets": 2300000,
    "depreciationandamortisationexpense": 300000,
    "impairmentloss": 2100000,
    "noncurrentassetsexcludingdeferredtaxassets": 8300000,
    "revenuefromperformanceobligationssatisfiedorpartiallysatisfiedinpreviousperiods": 47100000,
    "revenuerecognitionmilestonemethodrevenuerecognized": 53000000,
    "percentageofsharesindevelopmentcost": 0.45,
    "percentageonprovisionofservices": 0.45,
    "percentageofclinicaltrialservices": 0.55,
    "percentageoffuturedevelopmentcostsforclinicaltrials": 1,
    "financialassetsatfairvalue": 46500000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 8400000,
    "increasethroughoriginationorpurchasefinancialassets": 45090000,
    "decreasethroughderecognitionfinancialassets": 12677000,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibleincreaseinunobservableinputliabilities": -43100000,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibledecreaseinunobservableinputliabilities": 47700000,
    "increaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": 1100000,
    "decreaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsliabilities": -10100000,
    "wagesandsalaries": 99438000,
    "socialsecuritycontributions": 8043000,
    "expensefromsharebasedpaymenttransactionswithemployees": 325513,
    "temporarystaffexpense": 5760000,
    "otheremployeeexpense": 9664000,
    "employeebenefitsexpense": 131860000,
    "averagenumberofemployees": 564000000,
    "postemploymentbenefitexpensedefinedcontributionplans": 800000,
    "numberofemployees": 133,
    "gainlossoncessationofconsolidationofsubsidiariesduetochangeofinvestmententitystatus": 379000,
    "netforeignexchangegain": 13656000,
    "revenuefromgovernmentgrants": 61000,
    "miscellaneousoperatingincome": 489000,
    "netforeignexchangeloss": 4581000,
    "miscellaneousexpenses": 594000,
    "foreigncurrencygainsfromfinancialassetsfromcollaborations": 66379000,
    "gainfromchangesofestimatesinfinancialassetsfromcollaborations": 15616000,
    "gainslossesonhedgesofnetinvestmentsinforeignoperationsnetoftax": 698000,
    "gainsonchangeinfairvalueofderivatives": 8121000,
    "interestincomeforfinancialassetsmeasuredatamortisedcost": 1233000,
    "foreigncurrencylossesfromfinancialliabilitiesfromcollaborations": -5549000,
    "effectiveinterestexpensesfromfinancialliabilitiesfromcollaborations": -15329000,
    "lossesfromchangesofestimatesinfinanicalliabilitiesfromcollaborations": -24565000,
    "lossesfromforeigncurrencyhedging": -4950000,
    "lossesonchangeinfairvalueofderivatives": 32138000,
    "interestexpenseonfinancialassetsmeasuredatamortizedcost": 9391000,
    "interestexpenseonleaseliabilities": 1173000,
    "interestexpenseonfinancialliabilitiesmeasuredatamortizedcost": 2454000,
    "bankandsimilarcharges": 664000,
    "gainlossonfinancialinstruments": -1771000,
    "corporatetaxrate": -0.15,
    "solidaritysurchargerate": -0.055,
    "effectivetradetaxrate": -0.1085,
    "federalcorporateincometaxrate": 0.21,
    "stateincometaxrate": 0.0411,
    "applicabletaxrate": 0.26675,
    "deferredtaxassetsrecognized": 3200000,
    "percentageofincometaxable": 0.2511,
    "combinedeffectivetaxrate": 0.2668,
    "incometaxespaidrefund": 75400000,
    "currenttaxexpenseincome": 1300000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": 10600000,
    "deferredtaxexpenseincome": 153100000,
    "currentanddeferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 12800000,
    "adjustmentsforcurrenttaxofpriorperiod": 66000,
    "accountingprofit": -22492000,
    "taxexpenseincomeatapplicabletaxrate": 6000000,
    "premiumfromcapitalincreasebyincyte": 14182000000,
    "taxeffectofsharebasedcompensation": 1823000,
    "taxeffectsofpermanentdifferences": 4991000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 9718000,
    "taxeffectfromrecognitionofdeferredtaxassetsontemporarydifferences1": 6548000000,
    "taxeffectfromrecognitionofdeferredtaxassetsoncurrentyeartaxlosses1": 66472000000,
    "taxeffectofforeigntaxrates": -140000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": -607000,
    "averageeffectivetaxrate": 3.352,
    "prioryeartaxlossescarryforwards": 20435000,
    "reclassificationtotemporarydifference": -27453000,
    "expiryordeconsolidation": -20435000,
    "utilizationoftaxlosses": -249193000,
    "deferredtaxliabilities": 5100000,
    "deferredtaxassetsoffsetting": -19670000,
    "deferredtaxliabilitiesoffsetting": -19670000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 642000,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": 12733806,
    "weightedaverageshares": 32525644,
    "sharesinentityheldbyentityorbyitssubsidiariesorassociates": 225800,
    "increasedecreaseinnumberofordinarysharesissued": 725953,
    "effectoftransferoftreasurystock": 4709,
    "interestinconnectionwithdilutiveshares": 654487,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": 98545063,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 642208,
    "cash": 109797000,
    "cashandcashequivalentsaccumulatedimpairments": 2000,
    "netgainfromdisposalofavailableforsalefinancialassets": 6100000,
    "netgainfromdisposaloffinancialassetsatfairvaluethroughprofitandloss": 500000,
    "accountsreceivablenoninterestbearingpaymentterms": "between 30 and 180 days",
    "incometaxreceivables": 400000,
    "cashflowprojectionperiod": "P10Y",
    "betafactor": 0.009,
    "weightedaveragecostofcapitalbeforetaxpercentage": 0.085,
    "descriptionofgrowthrateusedtoextrapolatecashflowprojections": 0.01,
    "descriptionofmethodsandassumptionsusedinpreparingsensitivityanalysisforactuarialassumptions": "A change in the pre-tax WACC of +/&#8211;1.0% would cause a &#8364; 0.1 million lower or &#8364; 0.1 million higher amount of equity.",
    "longtermrestrictedcash": 1200000,
    "fairvalueofinvestmentsinequityinstrumentsdesignatedasmeasuredatfairvaluethroughothercomprehensiveincome": 15300000,
    "intangibleassetsandgoodwill": 28200000,
    "assetssoldorrepledgedascollateralatfairvalue": 200000,
    "currentrawmaterialsandcurrentproductionsupplies": 5300000,
    "finishedgoods": 4700000,
    "impairmentoncombinationcompounds": 500000,
    "propertyplantandequipmentacquisitioncost": 400000,
    "milestonepaymentswerecapitalized": 56400000,
    "cumulativegainlossondisposalofinvestmentsinequityinstrumentsdesignatedasmeasuredatfairvaluethroughothercomprehensiveincome": 300000,
    "intangibleassetacquisitioncost": 32500000,
    "amortisationintangibleassetsotherthangoodwill": 2240000,
    "availableforsalefinancialassetsmaturity": "Daily",
    "availableforsalefinancialassetscost": 288050000,
    "grossunrealizedgainsonfinancialassetsavailableforsale": 293000,
    "grossunrealizedlossesonfinancialassetsavailableforsale": 405000,
    "currentfinancialassetsavailableforsale": 287938000,
    "loansandreceivablesmaturity": "More than 12 Months",
    "grossunrealizedgainsonloansandreceivables": -652000,
    "grossunrealizedlossesonloansandreceivables": 587000,
    "currentloansandreceivables": 846301000,
    "prepaidexpensesandothercurrentassetsconsistedofcombinationcompounds": 10003000,
    "receivablesfrominputtaxsurplus": 3920000,
    "currentprepaidexpenses": 777000,
    "othercurrentprepayments": 4711000,
    "prepaidexpensesandothercurrentassets": 20621000,
    "depreciationpropertyplantandequipment": 2464000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 4334000,
    "disposalspropertyplantandequipment": 923000,
    "depreciationexpense": 2487000,
    "additionstorightofuseassets": 4868000,
    "depreciationrightofuseassets": 1352000,
    "disposalofrightofuseassets": -78000,
    "leaseliabilities": 45019000,
    "additionforleaseliabilities": 5286000,
    "disposalsforleaseliabilities": -79000,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 81000,
    "impactonprofitorlossduetoadoptionoflease": -4840000,
    "netleaseliabilities": 53088000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 44881000,
    "impairmentlossrecognisedinprofitorlossintangibleassetsandgoodwill": 16026000,
    "disposalsintangibleassetsandgoodwill": 32093000,
    "increasedecreasethroughtransfersintangibleassetsandgoodwill": -56449000,
    "impairmentlossrecognisedinprofitorlossintangibleassetsotherthangoodwill": 16026000,
    "percentageofvotingequityinterestsacquired": 0.172,
    "equitymethodinvestmentaccountedindomesticcurrency": -346691,
    "noncurrentprepaidexpenses": 183000,
    "othernoncurrentassets": 1384000,
    "noninterestbearingterm": "no more than 30 days",
    "auditorsremuneration": 1632883,
    "auditorsremunerationforauditrelatedservices": 70000,
    "taxprovisionsandcurrentandnoncurrentotherprovisions": 67500000,
    "increasedecreaseinissuedcapital": 932088,
    "weightedaverageexercisepriceofshareoptionsexercised": 31.88,
    "increasedecreasethroughconversionofconvertibleinstrumentsshares": 24647,
    "numberofsharesauthorised": 5307536,
    "cancellationofauthorizedordinarysharecapital": 2008536,
    "numberofordinarysharesofconditionalcapital": 6340760,
    "descriptionofconditionalcapital": "The aggregate nominal amount of the conditional capital created for the purpose of granting subscription rights to employees and members of the management of our Company or of an affiliated company may not exceed 10% of the share capital existing at the time of the shareholders&#8217; meeting adopting such resolution.",
    "numberoftreasuryshares": 131414,
    "increasedecreaseintrasurystockamountduetotransfer": 3488506,
    "transferoftreasurystock": 91037,
    "transferoftreasurystockamount": 3364727,
    "treasurysharestransferedtorelatedpartiesvalue": 123779,
    "treasurysharestransferedtorelatedpartiesnumberofshares": 3349,
    "increaseinadditionalpaidincapital": 120801938,
    "conditionalcapitalcreated": 500000000,
    "debtinstrumentmaturitydate": "2025-10-16",
    "debtinstrumentconvertiblenumberofequityinstruments": 2475436,
    "debtcouponrate": 0.00625,
    "debtconversionprice": 131.29,
    "debtconversionpremiumpercentage": 0.4,
    "debtinstrumentreferenceprice": 93.7766,
    "redemptionpercentageofdebtinstrumentwhenmarketpriceofsharesfalldown": 1.3,
    "redemptionpercentagebasedonoutstandingnominalamount": 0.2,
    "proportionofvotingpowerheldinsubsidiary": 0.3,
    "paymentsfordebtissuecosts": 5100000,
    "debtinstrumentconversionrightsecuredcollateralamount": 49200000,
    "financialliabilitiesatamortisedcost": 270700000,
    "aggregatedifferencebetweenfairvalueatinitialrecognitionandamountdeterminedusingvaluationtechniqueyettoberecognised": 325000000,
    "increasedecreaseinissuedcapitalshares": 3692764,
    "increasedecreasethroughconversionofconvertibleinstruments": 24647,
    "authorizedcapital": 79590657,
    "debtrelatedtransactioncost": 100370,
    "debtinstrumentcovertiblebondoptionshares": 49994274,
    "convertibledebtinstrumenttransactioncost": 777418,
    "auditorsremunerationforotherservices": 1650,
    "licensepayable": 259000,
    "accruedliabilities": 79200000,
    "othercurrentliabilities": 1536000,
    "accountspayableandaccruedexpensescurrent": 128554000,
    "externallaboratoryservices": 43500000,
    "accruedpersonnelexpensesforpaymentstoemployeesandmanagement": 17320000,
    "accruedoutstandingexpense": 15236000,
    "accruedrevenuedeductionsfromproductsales": 943000,
    "expensesforlegaladvice": 472000,
    "auditfeesandotherauditrelatedcosts": 683000,
    "licensepayments": 1046000,
    "accruedliabiitycurrent": 79200000,
    "taxprovisionsandcurrentandnoncurrentotherprovisionsadditions": 67138000,
    "taxprovisionsandcurrentandnoncurrentotherprovisionsutilized": 323000,
    "contractliabilities": 2616000,
    "contractliabilitiesprepaymentsreceived": 13430000,
    "revenuethatwasincludedincontractliabilitybalanceatbeginningofperiod": 1571000,
    "revenuerecognizedforreceivedprepaymentsandservicesperformed": 10929000,
    "increasedecreaseinnumberthroughtransferoftreasuryshares": -94386,
    "dateofgrantofsharebasedpaymentarrangement": "April 21, 2020",
    "sharebasedcompensationvestingperiod": "P4Y",
    "numberofsharesubscriptionrightsgranted": 2,
    "exercisepriceshareoptionsgranted2019": 81.04,
    "descriptionofexerciseperiodofsharebasedarrangement": "The exercise period is three years after the end of the four-year vesting period/performance period, which is March 31, 2027.",
    "holdingperiodorperformanceperiodtoissuetotalnumberofshares": "P4Y",
    "fairvalueofstockoptionsgranted": 11532252,
    "numberofoutstandingshareoptions": 10651,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 7137,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": -91037,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": -2537,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 11881,
    "weightedaverageshareprice2019": 93.66,
    "weightedaveragesharepriceshareoptionsgranted2019": 93.82,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.2288,
    "performancetermofsharebasedprogram": "P3Y5M1D",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0084,
    "weightedaveragefairvalueatmeasurementdateshareoptionsgranted": 93.82,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 9047,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 13677,
    "percentageofachievementofperformancecriteriaexceeded": 2,
    "percentageofperformancesharesvested": 0.25,
    "numberofperformancesharesallocatedpercentage": 1,
    "sharebasedcompensationbysharebasedpaymentarrangementadjustmentduetoperformancecriteria": 35035,
    "weightedaveragefairvalueatmeasurementdateotherequityinstrumentsgranted": 93.82,
    "expensefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 800000,
    "numberofsharesissuedtorelatedparties": 1600,
    "numberofsharesissuedtorelatedpartiesduringperiodadditions": 13677,
    "numberofsharesissuedtorelatedpartiessales": 9000,
    "percentageofthresholdtotriggerchangeofcontrolinmanagementremuneratincontracts": 0.3,
    "percentageofgrossfixedsalaryandannualbonus": 2,
    "keymanagementpersonnelcompensation": 14254807,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 400000,
    "keymanagementpersonnelcompensationterminationbenefits": 2443409,
    "percentageofseverancepayment": 0.5,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 424300,
    "performanceunrelatedremunerationforkeymaagerialpersonnel": 5529112,
    "performancerelatedremunerationofkeymanagerialpersonnel": 2478346,
    "keymanagementpersonnelcompensationsharebasedpayment": 487327,
    "postemploymentbenefits": 2443409,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 7261119,
    "futuremilestonepaymentsduefornexttwelvemonths": 12500000,
    "minimumrentalperiod": "P12M",
    "periodtillwhichtheroyaltyobligationcontinues": "P11Y",
    "futureminimumleasespaymentsoflowvalueassetsandothershorttermleases": 44000,
    "futureminimumpaymentsperformanceshareandunitprograms": 1868000,
    "othercommitment": 7406000,
    "contractualobligation": 10310000,
    "futurepaymentcommitmentsforclinicalstudies": 193300000
  },
  {
    "date": "2019-12-31",
    "symbol": "MOR",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "MOR",
    "documentannualreport": "true",
    "entityregistrantname": "MorphoSys AG",
    "entitycentralindexkey": 1340243,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "001-38455",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Large Accelerated Filer",
    "entityshellcompany": "false",
    "documentshellcompanyreport": "false",
    "entityemerginggrowthcompany": "false",
    "entitycommonstocksharesoutstanding": 31839572,
    "security12btitle": "Ordinary Shares, no par value",
    "securityexchangename": "NASDAQ",
    "entityaddresscountry": "DE",
    "entityinteractivedatacurrent": "Yes",
    "documentregistrationstatement": "false",
    "documenttransitionreport": "false",
    "revenue": 29100000,
    "costofsales": 8685000,
    "researchanddevelopmentexpense": 5944000,
    "sellingexpense": 371000,
    "generalandadministrativeexpense": 1739000,
    "operatingexpense": 25723000,
    "otherincome": 680000,
    "otherexpensebynature": 19000,
    "profitlossfromoperatingactivities": -107919581,
    "financeincome": 2799473,
    "financecosts": 2272369,
    "impairmentlossreversalofimpairmentlossrecognisedonfinancialassets": 872000,
    "incometaxexpensecontinuingoperations": -3506419,
    "profitloss": -103014058,
    "basicanddilutedearningslosspershare": -3.26,
    "weightedaveragenumberofequitysharesusedincomputingearningspersharebasicanddiluted": 31611155,
    "othercomprehensiveincomenetoftaxgainslossesfrominvestmentsinequityinstruments": -1160160,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 75332,
    "othercomprehensiveincome": -1084828,
    "comprehensiveincome": -104098886,
    "cashandcashequivalents": 44314000,
    "financialassetsatfairvaluethroughprofitorloss": 20455000,
    "currentfinancialassetsatamortisedcost": 207735000,
    "tradereceivablesandcontractassets": 15081702,
    "currentincometaxreceivables": 145817,
    "othercurrentreceivables": 1613254,
    "inventories": 288212,
    "currentprepaymentsandothercurrentassets": 14059627,
    "currentassets": 280460000,
    "propertyplantandequipment": 1921000,
    "rightofuseassets": 336000,
    "copyrightspatentsandotherindustrialpropertyrightsserviceandoperatingrights": 2981282,
    "licencesandfranchises": 2350002,
    "inprocessresearchanddevelopmentprograms": 35683709,
    "computersoftware": 107137,
    "goodwill": 3700000,
    "noncurrentfinancialassetsatamortisedcost": 84922000,
    "noncurrentfinancialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 387000,
    "noncurrentprepaidexpensesandotherassets": 1136030,
    "noncurrentassets": 107967000,
    "assets": 388427000,
    "accountspayableandaccrualscurrent": 57041902,
    "currentleaseliabilities": 2026000,
    "currenttaxprovisions": 94732,
    "otherprovisions": 323000,
    "currentcontractliabilities": 1570801,
    "convertiblebondsduetocurrentrelatedparties": 12324,
    "currentliabilities": 22505000,
    "noncurrentleaseliabilities": 40042000,
    "noncurrentprovisions": 23166,
    "noncurrentcontractliabilities": 114927,
    "convertiblebondsduetorelatedparties": 12.324,
    "othernoncurrentliabilities": 700000,
    "noncurrentliabilities": 6633000,
    "liabilities": 101737530,
    "issuedcapital": 31957958,
    "treasuryshares": 8357250,
    "additionalpaidincapital": 628176568,
    "reserveofmiscellaneousothercomprehensiveincome": -1295718,
    "retainedearnings": -255779786,
    "equity": 394702000,
    "equityandliabilities": 423840000,
    "numberofsharesissued": 31839572,
    "numberofsharesoutstanding": 31732158,
    "numberoftreasurysharesissued": 225800,
    "equitybeginningbalanceshares": 281036,
    "increasedecreasethroughsharebasedpaymenttransactions": 6654470,
    "exerciseofconvertiblebondsissuedtorelatedparties": 3773554,
    "exerciseofconvertiblebondsissuedtorelatedpartiesshares": 118386,
    "saleorissueoftreasuryshares": -1934043,
    "saleorissueoftreasurysharesshares": -52328,
    "saleorissueoftreasurysharestorelatedparties": -107480,
    "saleorissueoftreasurysharestorelatedpartiesshares": -2908,
    "equityendingbalanceshares": 225800,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 2317489,
    "adjustmentsfordepreciationandamortisationexpense": 6245162,
    "adjustmentinnetgainlossonsalesoffinancialassetsatfairvaluethroughprofitorloss": -752257,
    "adjustmentinnetgainlossonsalesoffinancialassetsatamortizedcost": -705952,
    "adjustmentinimpairmentlossreversalofimpairmentlossrecognisedonfinancialassets": 872000,
    "proceedsfromderivativefinancialinstruments": 931595,
    "adjustmentsfordecreaseincreaseinderivativefinancialassets": -1261618,
    "adjustmentsforgainlossondisposalspropertyplantandequipment": 21408,
    "increasedecreasethroughcumulativecatchupadjustmentstorevenuecontractliabilities": 5335977,
    "adjustmentsforsharebasedpayments": 6654470,
    "adjustmentsforincometaxexpense": -3506419,
    "adjustmentsfordecreaseincreaseintradeaccountsreceivableandcontractassets": 2667232,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -4422409,
    "adjustmentsfordecreaseincreaseinaccountspayableandaccrualstaxprovisionsandotherprovisions": 13202429,
    "adjustmentsforincreasedecreaseinotherliabilities": 316288,
    "adjustmentsforincreasedecreaseindeferredincome": 6069450,
    "incometaxespaidclassifiedasoperatingactivities": 62560,
    "cashflowsfromusedinoperatingactivities": -80138639,
    "purchaseofavailableforsalefinancialassets": 28305339,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 53159814,
    "purchaseoffinancialinstrumentsclassifiedasinvestingactivities": 246461961,
    "proceedsfromsalesormaturityoffinancialinstrumentsclassifiedasinvestingactivities": 318720000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 3103330,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 20469,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 562314,
    "purchaseoffinancialassetsatfairvaluethroughothercomprehensiveincome": 15004996,
    "interestreceivedclassifiedasinvestingactivities": 90156,
    "cashflowsfromusedininvestingactivities": 78552499,
    "proceedsinconnectionwithconvertiblebondsgrantedtorelatedparties": 3714361,
    "interestpaidclassifiedasfinancingactivities": 1011321,
    "cashflowsfromusedinfinancingactivities": 353239,
    "effectofexchangeratechangesoncashandcashequivalents": 87115,
    "increasedecreaseincashandcashequivalents": -1145786,
    "weightedaveragelesseesincrementalborrowingrateappliedtoleaseliabilitiesrecognisedatdateofinitialapplicationofifrs16": 0.0217,
    "leaseliabilities": 40783000,
    "currentprepaidexpenses": 500000,
    "noncurrentprepaidexpenses": 134000,
    "othercurrentliabilities": 1059000,
    "proportionofindirectownershipinterestinsubsidiary": 1,
    "maximumexposuretocreditriskondebtinstruments": 20500000,
    "receivablesfromcontractswithcustomers": 8000000,
    "percentageofaccountsreceivable": 0.005,
    "percentageofrevenuefromtopcustomer": 0.13,
    "maximumexposuretocreditriskonfinancialguarantees": 1000000,
    "unsettledforwardrateagreements": 1,
    "derivativefinancialinstrumentsunrealizedgrossgainloss": 400000,
    "increasedecreaseinincomeduetochangeinforeignexchangerates": 7900000,
    "increaseinvariableinterestrate": 0.005,
    "decreaseinvariableinterestrate": 0.005,
    "increaseinnetearnings": 300000,
    "decreaseinnetearnings": 300000,
    "descriptionofcreditdefaultswaps": "The Group currently classifies an increase in credit risk on debt instruments as significant when the premium on a counterparty credit default swap has increased by 100 basis points since the initial recognition of the instrument (Level 2).",
    "equityratiopercentage": 0.795,
    "dilutednumberofshares": 57035,
    "antidilutivesharesofinstrumentswithpotentialfuturedilutiveeffectnotincludedincalculationofdilutedearningsshares": 115684,
    "descriptionofusefullifepropertyplantandequipment": "3 - 5 years",
    "mandatoryapplicationforfinancialyearsstartingdate": "01/01/2020",
    "adoptedbytheeuropeanunionstatus": "yes",
    "impactonmorphosysstatus": "none",
    "operatingleasecommitments": 22530000,
    "commitmentsfornotidentifiableassets": -90000,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 56000,
    "otherleasecommitments": 28000,
    "grossleaseliabilitiesbeforeadjustmentsforextensionoptions": 22412000,
    "adjustmentsasaresultofdifferentassessmentofextensionoptions": 26855000,
    "grossleaseliabilities": 49267000,
    "undiscountedexcessliability": 8484000,
    "possibleimpactonmorphosysstatus": "none",
    "purchasedateofshares": "July 2018",
    "basisofconsolidationbeginningdate": "07/02/2018",
    "impairmentlossonfinancialasset": -379000,
    "unusedprovisionamountsreversed": 962000,
    "increasedecreaseinimpairmentlossforcreditriskrecognizedinprofitorloss": -80000,
    "increasedecreaseinimpairmentstages": -79000,
    "internalcreditrating": "low",
    "descriptionofrecognitionofexpectedcreditlossprovision": "Lifetime Expected Credit Losses",
    "grosscarryingamountoffinancialassets": 15162000,
    "impairmentlossonfinancialassets": -872000,
    "financialassets": 389334000,
    "averageimpairmentrate": 0.005,
    "currenttradereceivables": 15082000,
    "currenttradereceivablesgross": 15161702,
    "impairmentlossreversalofimpairmentlossrecognisedinprofitorlosstradereceivables": 80000,
    "tradeaccountspayable": 10655014,
    "financialassetsatamortisedcost": 292657371,
    "currentrestrictedcashandcashequivalents": 989000,
    "foreigncurrencyriskexposurenet": 316467939,
    "otherreceivables": 1613000,
    "thereoffinancialassets": 1217000,
    "hedginginstrumentassets": 396000,
    "currentfinancialassets": 289199000,
    "othercurrentnonfinancialassets": 147000,
    "noncurrentfinancialassets": 100135000,
    "convertiblebondsliabilitycomponent": 12000,
    "currentfinancialliabilities": 59569000,
    "noncurrentfinancialliabilities": 40042000,
    "financialliabilities": 99611000,
    "equitycapitalpercentage": 0.795,
    "liabilitiescapitalpercentage": 0.205,
    "depreciationratepropertyplantandequipment": 0.25,
    "amortisationrateintangibleassetsotherthangoodwill": 0.2,
    "segmentresult": -108098000,
    "segmentprofitlossfromoperatingactivities": -107920000,
    "profitlossbeforetax": -106521000,
    "additionspropertyplantandequipmentandintangibleassets": 207000,
    "depreciationandamortisationexpense": 355000,
    "impairmentloss": 1600000,
    "noncurrentassetsexcludingdeferredtaxassets": 4400000,
    "revenuefromperformanceobligationssatisfiedorpartiallysatisfiedinpreviousperiods": 62000000,
    "wagesandsalaries": 43476000,
    "socialsecuritycontributions": 5686000,
    "expensefromsharebasedpaymenttransactionswithemployees": 296415,
    "temporarystaffexpense": 2633000,
    "otheremployeeexpense": 5264000,
    "employeebenefitsexpense": 63713000,
    "averagenumberofemployees": 374,
    "numberofemployees": 116,
    "postemploymentbenefitexpensedefinedcontributionplans": 700000,
    "netforeignexchangegain": 233000,
    "revenuefromgovernmentgrants": 98000,
    "miscellaneousoperatingincome": 474000,
    "netforeignexchangeloss": 413000,
    "miscellaneousexpenses": 214000,
    "gainsonchangeinfairvalueofderivatives": 1476000,
    "gainonavailableforsalefinancialassetsandbonds": 1101000,
    "interestincomeforfinancialassetsmeasuredatamortisedcost": 223000,
    "lossesonchangeinfairvalueofderivatives": 214000,
    "lossonavailableforsalefinancialassetsandbonds": 299000,
    "interestexpenseonfinancialassetsmeasuredatamortizedcost": 796000,
    "interestexpenseonleaseliabilities": 932000,
    "bankandsimilarcharges": 31000,
    "gainlossonfinancialinstruments": 1202000,
    "corporatetaxrate": 0.217,
    "solidaritysurchargerate": 0.055,
    "effectivetradetaxrate": 0.1085,
    "federalcorporateincometaxrate": 0.21,
    "stateincometaxrate": 0.08,
    "applicabletaxrate": 0.25,
    "profitlossofcombinedentity": 200,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 76000000,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 600000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 1400000,
    "averageeffectivetaxrate": 0.113,
    "taxeffectfromchangeintaxrate": 1789000,
    "currenttaxexpenseincome": 1000,
    "deferredtaxexpenseincome": -3507000,
    "accountingprofit": -106520000,
    "taxexpenseincomeatapplicabletaxrate": -28414000,
    "taxeffectofsharebasedcompensation": 387000,
    "taxeffectsofpermanentdifferences": -101000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 151000,
    "taxeffectofdifferencesinprofitandlossadjustment": 310000,
    "taxeffectfromnonrecognitionofdeferredtaxassetsoncurrentyeartaxlosses1": 24285000,
    "taxeffectofforeigntaxrates": 1461000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 2000,
    "prioryeartaxlossescarryforwards": 194795000,
    "currentyeartaxlossescarryforwards": 121061000,
    "taxlossescarryforwardsexpiredduringperiod": -4000,
    "taxlossescarryforwards": 315852000,
    "expecteddeferredtaxassetsontaxlosses": 79939000,
    "valuationallowancefordeferredtaxassetsontaxlosses": 76096000,
    "capitalizeddeferredtaxassetsontaxlosses": 3843000,
    "deferredtaxassets": 3873000,
    "deferredtaxliabilities": 350000,
    "deferredtaxassetsoffsetting": -11982000,
    "deferredtaxliabilitiesoffsetting": -11982000,
    "weightedaverageshares": 31611155,
    "sharesinentityheldbyentityorbyitssubsidiariesorassociates": 281036,
    "effectoftransferoftreasurystock": 73,
    "cash": 44314000,
    "netgainfromdisposalofavailableforsalefinancialassets": 400000,
    "netgainfromdisposaloffinancialassetsatfairvaluethroughprofitandloss": 100000,
    "accountsreceivablenoninterestbearingpaymentterms": "between 30 and 45 days",
    "tradeandunbilledreceivables": 13400000,
    "incometaxreceivables": 100000,
    "prepaidexpensesandothercurrentassetsconsistedofcombinationcompounds": 4800000,
    "receivablesfrominputtaxsurplus": 3500000,
    "othercurrentprepayments": 4600000,
    "impairmentoncombinationcompounds": 700000,
    "impairmentlossrecognisedinprofitorlosspropertyplantandequipment": 10000,
    "impairmentlossrecognisedinprofitorlossintangibleassetsotherthangoodwill": 200000,
    "intangibleassetspledgedassecurityforliabilities": 11700000,
    "intangibleassetspledgedassecurityrelatedtogovernmentgrantsincludedinotherliabilities": 1500000,
    "intangibleassetsotherthangoodwill": 100000,
    "carryingamountofintangibleassetsdeclined": 100000,
    "additionsoffsetbyamortizationotherthangoodwill": 200000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 563000,
    "carryingamountofintangibleassetsdecreased": 1300000,
    "impairmentlossrecognisedinprofitorloss": 1300000,
    "intangibleassetswithindefiniteusefullife": 23900000,
    "cashflowprojectionperiod": "P10Y",
    "betafactor": 0.012,
    "weightedaveragecostofcapitalbeforetaxpercentage": 0.094,
    "descriptionofgrowthrateusedtoextrapolatecashflowprojections": 0.012,
    "descriptionofmethodsandassumptionsusedinpreparingsensitivityanalysisforactuarialassumptions": "A change in the pre-tax WACC of +/&#8211;1.0% would cause a &#8364; 0.1 million lower or &#8364; 0.1 million higher amount of equity.",
    "longtermrestrictedcash": 800000,
    "impairmentlossoninventory": 8700000,
    "percentageofvotingequityinterestsacquired": 0.134,
    "leaseterm": "P7Y",
    "cashoutflowforleases": 5000000,
    "leaseincentive": 700000,
    "fairvalueofinvestmentsinequityinstrumentsdesignatedasmeasuredatfairvaluethroughothercomprehensiveincome": 13700000,
    "intangibleassetsandgoodwill": 44798000,
    "assetssoldorrepledgedascollateralatfairvalue": 200000,
    "availableforsalefinancialassetsmaturity": "Daily",
    "availableforsalefinancialassetscost": 20330000,
    "grossunrealizedgainsonfinancialassetsavailableforsale": 125000,
    "currentfinancialassetsavailableforsale": 20455000,
    "financialassetsatamortizedcostmaturity": "More than 12 Months",
    "grossunrealizedgainsonfinancialassetsatamortizedcost": 18000,
    "grossunrealizedlossesonexpectedlossprovisioninconnectionwithifrs9financialassetsatamortizedcost": 97000,
    "depreciationpropertyplantandequipment": 1966000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 3099000,
    "disposalspropertyplantandequipment": 919000,
    "depreciationexpense": 1478000,
    "additionstorightofuseassets": 3459000,
    "depreciationrightofuseassets": 2805000,
    "additionforleaseliabilities": 4122000,
    "impactonprofitorlossduetoadoptionoflease": -3778000,
    "amortisationintangibleassetsotherthangoodwill": 3131000,
    "impairmentlossrecognisedinprofitorlossintangibleassetsandgoodwill": 1639000,
    "equitymethodinvestmentaccountedindomesticcurrency": 1542624,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -7703473,
    "financialassetsatfairvaluethroughothercomprehensiveincome": 387000,
    "othernoncurrentassets": 1002000,
    "noninterestbearingterm": "no more than 30 days",
    "accruedpersonnelexpensesforpaymentstoemployeesandmanagement": 14000000,
    "provisionsforoutstandinginvoices": 5600000,
    "externallaboratoryservices": 24400000,
    "licensepayments": 100000,
    "auditfeesandotherauditrelatedcosts": 700000,
    "expensesforlegaladvice": 300000,
    "auditorsremuneration": 1191435,
    "auditorsremunerationforauditservices": 872785,
    "auditorsremunerationforauditrelatedservices": 318650,
    "taxprovisionsandcurrentandnoncurrentotherprovisions": 441000,
    "increasedecreaseinissuedcapital": 118386,
    "weightedaverageexercisepriceofshareoptionsexercised": 31.88,
    "increasedecreasethroughconversionofconvertibleinstruments": 118386,
    "increasedecreasethroughconversionofconvertibleinstrumentsshares": 118386,
    "numberofsharesauthorised": 159197,
    "authorizedcapital": 159197,
    "numberofordinarysharesofconditionalcapital": 6340760,
    "descriptionofconditionalcapital": "The aggregate nominal amount of the conditional capital created for the purpose of granting subscription rights to employees and members of the management of our Company or of an affiliated company may not exceed 10% of the share capital existing at the time of the shareholders&#8217; meeting adopting such resolution.",
    "numberoftreasuryshares": 225800,
    "increasedecreaseintrasurystockamountduetotransfer": 107480,
    "transferoftreasurystock": 52328,
    "transferoftreasurystockamount": 1934043,
    "treasurysharestransferedtorelatedpartiesvalue": 107480,
    "treasurysharestransferedtorelatedpartiesnumberofshares": 2908,
    "increaseinadditionalpaidincapital": 8268115,
    "increaseinadditionalpaidincapitalfromtheexerciseofconvertiblebonds": 3655168,
    "increaseinadditionalpaidincapitalfromallocationofpersonnelexpensesresultingfromsharebasedpayments": 6654470,
    "licensepayable": 357000,
    "accruedliabilities": 44971000,
    "accountspayableandaccruedexpensescurrent": 57042000,
    "taxprovisionsandcurrentandnoncurrentotherprovisionsadditions": 1074000,
    "taxprovisionsandcurrentandnoncurrentotherprovisionsutilized": 827000,
    "taxprovisionsandcurrentandnoncurrentotherprovisionsreleased": 198000,
    "contractliabilities": 1686000,
    "contractliabilitiesprepaymentsreceived": 6070000,
    "revenuethatwasincludedincontractliabilitybalanceatbeginningofperiod": 794000,
    "revenuerecognizedforreceivedprepaymentsandservicesperformed": 4542000,
    "increasedecreaseinnumberthroughtransferoftreasuryshares": -55236,
    "dateofgrantofsharebasedpaymentarrangement": "April&#160;1, 2019",
    "sharebasedcompensationvestingperiod": "P4Y",
    "numberofsharesubscriptionrightsgranted": 2,
    "exercisepriceshareoptionsgranted2019": 81.04,
    "descriptionofexerciseperiodofsharebasedarrangement": "The exercise period is three years after the end of the four-year vesting period/performance period, which is March&#160;31, 2025.",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 83660,
    "percentageofachievementofperformanceconditions": 1,
    "weightedaveragefairvalueatmeasurementdateshareoptionsgranted": 126.8,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 1.815,
    "numberofbeneficiariesleft": 1,
    "numberofbeneficiariesassumedtoleaveinvestingperiod": 2,
    "increasedecreaseinnumberofshareoptions": 21163,
    "percentageoftargetexpectedtoachievetostockoptionsgrant": 1,
    "weightedaveragesharepriceshareoptionsgranted2019": 85,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.2646,
    "performancetermofsharebasedprogram": "P4Y",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0013,
    "convertiblebondsconversionpricepershare": 31.88,
    "percentageincreaseinshareprice": 1.2,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 10998,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 24647,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 27149,
    "numberofinstrumentsotherequityinstrumentsgranted": 9347,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 31.88,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 31.88,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P3M",
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 24647,
    "descriptionofperformancecriteriafulfillmentpercentage": "These criteria are approved annually by the Supervisory Board. The fulfillment of these criteria was set at 200% for one year, 54% for one year and 0% for two years.",
    "percentageofachievementofperformancecriteriaexceeded": 2,
    "percentageofperformancesharesvested": 0.25,
    "weightedaveragefairvalueatmeasurementdateotherequityinstrumentsgranted": 106.85,
    "numberofsharesissuedtorelatedparties": 2600,
    "numberofsharesissuedtorelatedpartiesduringperiodadditions": 250,
    "numberofsharesissuedtorelatedpartiessales": 48650,
    "numberofoutstandingshareoptions": 118974,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 18798,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 336772,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 107263,
    "keymanagementpersonnelcompensationsharebasedpayment": 123284,
    "keymanagementpersonnelcompensation": 3098966,
    "keymanagementpersonnelcompensationterminationbenefits": 2200000,
    "sharebasedpaymentarrangementvestingperiod": "P4Y",
    "percentageofthresholdtotriggerchangeofcontrolinmanagementremuneratincontracts": 0.3,
    "percentageofgrossfixedsalaryandannualbonus": 2,
    "futuremilestonepaymentsduefornexttwelvemonths": 37500000,
    "futuremilestonepaymentsdueyeartwo": 287000000,
    "futureminimumpaymentoflowvalueleaseassets": 100000,
    "othercommitment": 1532000,
    "contractualobligation": 1632000,
    "futurepaymentcommitmentsforclinicalstudies": 164700000
  }
]